<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">70130</article-id><article-id pub-id-type="doi">10.7554/eLife.70130</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-237885"><name><surname>Butner</surname><given-names>Joseph D</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0608-2580</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-237886"><name><surname>Martin</surname><given-names>Geoffrey V</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-216772"><name><surname>Wang</surname><given-names>Zhihui</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6262-700X</contrib-id><email>zwang@houstonmethodist.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-237887"><name><surname>Corradetti</surname><given-names>Bruna</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-237888"><name><surname>Ferrari</surname><given-names>Mauro</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-237889"><name><surname>Esnaola</surname><given-names>Nestor</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-237890"><name><surname>Chung</surname><given-names>Caroline</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-237891"><name><surname>Hong</surname><given-names>David S</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-237892"><name><surname>Welsh</surname><given-names>James W</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-237893"><name><surname>Hasegawa</surname><given-names>Naomi</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-237894"><name><surname>Mittendorf</surname><given-names>Elizabeth A</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-237895"><name><surname>Curley</surname><given-names>Steven A</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-237896"><name><surname>Chen</surname><given-names>Shu-Hsia</given-names></name><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund17"/><xref ref-type="other" rid="fund18"/><xref ref-type="other" rid="fund19"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-237897"><name><surname>Pan</surname><given-names>Ping-Ying</given-names></name><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund20"/><xref ref-type="other" rid="fund21"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-237898"><name><surname>Libutti</surname><given-names>Steven K</given-names></name><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="aff" rid="aff14">14</xref><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-71465"><name><surname>Ganesan</surname><given-names>Shridar</given-names></name><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-216776"><name><surname>Sidman</surname><given-names>Richard L</given-names></name><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-216782"><name><surname>Pasqualini</surname><given-names>Renata</given-names></name><xref ref-type="aff" rid="aff16">16</xref><xref ref-type="aff" rid="aff17">17</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund14"/><xref ref-type="other" rid="fund15"/><xref ref-type="other" rid="fund16"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-216139"><name><surname>Arap</surname><given-names>Wadih</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8686-4584</contrib-id><xref ref-type="aff" rid="aff16">16</xref><xref ref-type="aff" rid="aff18">18</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund14"/><xref ref-type="other" rid="fund15"/><xref ref-type="other" rid="fund16"/><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-63232"><name><surname>Koay</surname><given-names>Eugene J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7675-3461</contrib-id><email>EKoay@mdanderson.org</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund11"/><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-216773"><name><surname>Cristini</surname><given-names>Vittorio</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution>Mathematics in Medicine Program, Houston Methodist Research Institute</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Department of Imaging Physics, The University of Texas M.D. Anderson Cancer Center</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Department of Nanomedicine, Houston Methodist Research Institute</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Swansea University Medical School, Singleton Park</institution><addr-line><named-content content-type="city">Swansea</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff6"><label>6</label><institution>Department of Surgery, Houston Methodist Cancer Center</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Department of Investigational Cancer Therapeutics, The University of Texas M.D. Anderson Cancer Center</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution>University of Texas Health Science Center (UTHealth), McGovern Medical School</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution>Breast Oncology Program, Dana Farber/Brigham and Women's Cancer Center</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution>Michael E. DeBakey Department of Surgery, Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution>Immunotherapy Research Center, Houston Methodist Research Institute</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff12"><label>12</label><institution>Cancer Center, Houston Methodist Research Institute</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff13"><label>13</label><institution>Rutgers Cancer Institute of New Jersey</institution><addr-line><named-content content-type="city">New Brunswick</named-content></addr-line><country>United States</country></aff><aff id="aff14"><label>14</label><institution>Department of Surgery, Rutgers Robert Wood Johnson Medical School</institution><addr-line><named-content content-type="city">New Brunswick</named-content></addr-line><country>United States</country></aff><aff id="aff15"><label>15</label><institution>Department of Neurology, Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff16"><label>16</label><institution>Rutgers Cancer Institute of New Jersey</institution><addr-line><named-content content-type="city">Newark</named-content></addr-line><country>United States</country></aff><aff id="aff17"><label>17</label><institution>Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical School</institution><addr-line><named-content content-type="city">Newark</named-content></addr-line><country>United States</country></aff><aff id="aff18"><label>18</label><institution>Division of Hematology/Oncology, Department of Medicine, Rutgers New Jersey Medical School</institution><addr-line><named-content content-type="city">Newark</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Liu</surname><given-names>Caigang</given-names></name><role>Reviewing Editor</role><aff><institution>Shengjing Hospital of China Medical University</institution><country>China</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Senior Editor</role><aff><institution>Icahn School of Medicine at Mount Sinai</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>09</day><month>11</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e70130</elocation-id><history><date date-type="received" iso-8601-date="2021-05-06"><day>06</day><month>05</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-10-25"><day>25</day><month>10</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Butner et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Butner et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-70130-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-70130-figures-v2.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>Checkpoint inhibitor therapy of cancer has led to markedly improved survival of a subset of patients in multiple solid malignant tumor types, yet the factors driving these clinical responses or lack thereof are not known. We have developed a mechanistic mathematical model for better understanding these factors and their relations in order to predict treatment outcome and optimize personal treatment strategies.</p></sec><sec id="abs2"><title>Methods:</title><p>Here, we present a translational mathematical model dependent on three key parameters for describing efficacy of checkpoint inhibitors in human cancer: tumor growth rate (<italic>α</italic>), tumor-immune infiltration (<italic>Λ</italic>), and immunotherapy-mediated amplification of anti-tumor response (<italic>µ</italic>). The model was calibrated by fitting it to a compiled clinical tumor response dataset (n = 189 patients) obtained from published anti-PD-1 and anti-PD-L1 clinical trials, and then validated on an additional validation cohort (n = 64 patients) obtained from our in-house clinical trials.</p></sec><sec id="abs3"><title>Results:</title><p>The derived parameters <italic>Λ</italic> and <italic>µ</italic> were both significantly different between responding versus nonresponding patients. Of note, our model appropriately classified response in 81.4% of patients by using only tumor volume measurements and within 2 months of treatment initiation in a retrospective analysis. The model reliably predicted clinical response to the PD-1/PD-L1 class of checkpoint inhibitors across multiple solid malignant tumor types. Comparison of model parameters to immunohistochemical measurement of PD-L1 and CD8+ T cells confirmed robust relationships between model parameters and their underlying biology.</p></sec><sec id="abs4"><title>Conclusions:</title><p>These results have demonstrated reliable methods to inform model parameters directly from biopsy samples, which are conveniently obtainable as early as the start of treatment. Together, these suggest that the model parameters may serve as early and robust biomarkers of the efficacy of checkpoint inhibitor therapy on an individualized per-patient basis.</p></sec><sec id="abs5"><title>Funding:</title><p>We gratefully acknowledge support from the Andrew Sabin Family Fellowship, Center for Radiation Oncology Research, Sheikh Ahmed Center for Pancreatic Cancer Research, GE Healthcare, Philips Healthcare, and institutional funds from the University of Texas M.D. Anderson Cancer Center. We have also received Cancer Center Support Grants from the National Cancer Institute (P30CA016672 to the University of Texas M.D. Anderson Cancer Center and P30CA072720 the Rutgers Cancer Institute of New Jersey). This research has also been supported in part by grants from the National Science Foundation Grant DMS-1930583 (ZW, VC), the National Institutes of Health (NIH) 1R01CA253865 (ZW, VC), 1U01CA196403 (ZW, VC), 1U01CA213759 (ZW, VC), 1R01CA226537 (ZW, RP, WA, VC), 1R01CA222007 (ZW, VC), U54CA210181 (ZW, VC), and the University of Texas System STARS Award (VC). BC acknowledges support through the SER Cymru II Programme, funded by the European Commission through the Horizon 2020 Marie Skłodowska-Curie Actions (MSCA) COFUND scheme and the Welsh European Funding Office (WEFO) under the European Regional Development Fund (ERDF). EK has also received support from the Project Purple, NIH (U54CA210181, U01CA200468, and U01CA196403), and the Pancreatic Cancer Action Network (16-65-SING). MF was supported through NIH/NCI center grant U54CA210181, R01CA222959, DoD Breast Cancer Research Breakthrough Level IV Award W81XWH-17-1-0389, and the Ernest Cockrell Jr. Presidential Distinguished Chair at Houston Methodist Research Institute. RP and WA received serial research awards from AngelWorks, the Gillson-Longenbaugh Foundation, and the Marcus Foundation. This work was also supported in part by grants from the National Cancer Institute to SHC (R01CA109322, R01CA127483, R01CA208703, and U54CA210181 CITO pilot grant) and to PYP (R01CA140243, R01CA188610, and U54CA210181 CITO pilot grant). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></sec></abstract><kwd-group kwd-group-type="author-keywords"><kwd>immunotherapy</kwd><kwd>biomarkers</kwd><kwd>patient stratification</kwd><kwd>translational research</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>DMS-1930583</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Zhihui</given-names></name><name><surname>Cristini</surname><given-names>Vittorio</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>1R01CA253865</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Zhihui</given-names></name><name><surname>Cristini</surname><given-names>Vittorio</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>1U01CA196403</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Zhihui</given-names></name><name><surname>Koay</surname><given-names>Eugene J</given-names></name><name><surname>Cristini</surname><given-names>Vittorio</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>1U01CA213759</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Zhihui</given-names></name><name><surname>Cristini</surname><given-names>Vittorio</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>1R01CA226537</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Zhihui</given-names></name><name><surname>Pasqualini</surname><given-names>Renata</given-names></name><name><surname>Arap</surname><given-names>Wadih</given-names></name><name><surname>Cristini</surname><given-names>Vittorio</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>1R01CA222007</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Zhihui</given-names></name><name><surname>Cristini</surname><given-names>Vittorio</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>U54CA210181</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Zhihui</given-names></name><name><surname>Ferrari</surname><given-names>Mauro</given-names></name><name><surname>Chen</surname><given-names>Shu-Hsia</given-names></name><name><surname>Pan</surname><given-names>Ping-Ying</given-names></name><name><surname>Koay</surname><given-names>Eugene J</given-names></name><name><surname>Cristini</surname><given-names>Vittorio</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P30CA016672</award-id><principal-award-recipient><name><surname>Hong</surname><given-names>David S</given-names></name><name><surname>Welsh</surname><given-names>James W</given-names></name><name><surname>Koay</surname><given-names>Eugene J</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P30CA072720</award-id><principal-award-recipient><name><surname>Libutti</surname><given-names>Steven K</given-names></name><name><surname>Ganesan</surname><given-names>Shridar</given-names></name><name><surname>Pasqualini</surname><given-names>Renata</given-names></name><name><surname>Arap</surname><given-names>Wadih</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000780</institution-id><institution>European Commission</institution></institution-wrap></funding-source><award-id>SER Cymru II Programme</award-id><principal-award-recipient><name><surname>Corradetti</surname><given-names>Bruna</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>U01CA200468</award-id><principal-award-recipient><name><surname>Koay</surname><given-names>Eugene J</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01CA222959</award-id><principal-award-recipient><name><surname>Ferrari</surname><given-names>Mauro</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution>DOD Breast Cancer Research</institution></institution-wrap></funding-source><award-id>Breakthrough Level IV Award W81XWH-17-1-0389</award-id><principal-award-recipient><name><surname>Ferrari</surname><given-names>Mauro</given-names></name></principal-award-recipient></award-group><award-group id="fund14"><funding-source><institution-wrap><institution>AngelWorks</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Pasqualini</surname><given-names>Renata</given-names></name><name><surname>Arap</surname><given-names>Wadih</given-names></name></principal-award-recipient></award-group><award-group id="fund15"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010470</institution-id><institution>Gillson Longenbaugh Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Pasqualini</surname><given-names>Renata</given-names></name><name><surname>Arap</surname><given-names>Wadih</given-names></name></principal-award-recipient></award-group><award-group id="fund16"><funding-source><institution-wrap><institution>Marcus Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Pasqualini</surname><given-names>Renata</given-names></name><name><surname>Arap</surname><given-names>Wadih</given-names></name></principal-award-recipient></award-group><award-group id="fund17"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01CA109322</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Shu-Hsia</given-names></name></principal-award-recipient></award-group><award-group id="fund18"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01CA127483</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Shu-Hsia</given-names></name></principal-award-recipient></award-group><award-group id="fund19"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01CA208703</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Shu-Hsia</given-names></name></principal-award-recipient></award-group><award-group id="fund20"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01CA140243</award-id><principal-award-recipient><name><surname>Pan</surname><given-names>Ping-Ying</given-names></name></principal-award-recipient></award-group><award-group id="fund21"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01CA188610</award-id><principal-award-recipient><name><surname>Pan</surname><given-names>Ping-Ying</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A mechanistic mathematical model informed by standard‐of‐care imaging and pathology predicts tumor responses to immunotherapy a priori on a per-patient basis.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Recent advances in the understanding of immunological pathways responsible for antibody- and/or cell-mediated destruction of tumors have led to the development of unique cancer therapeutics in recent years, leading to markedly improved survival in the setting of previously intractable metastatic melanoma, bladder, kidney, lung, and head and neck cancers, among several other human solid tumor types (<xref ref-type="bibr" rid="bib4">Borghaei et al., 2015</xref>; <xref ref-type="bibr" rid="bib54">Robert et al., 2015a</xref>; <xref ref-type="bibr" rid="bib55">Robert et al., 2015b</xref>). In particular, one of the most successful clinical applications of immune checkpoint inhibitors includes antibodies directed against the programmed death protein 1 (PD-1) pathway, which inhibits cellular immune killing of cancer cells via complementary binding of tumor expressed programmed death ligand 1 (PD-L1) to PD-1 on immune cells (<xref ref-type="bibr" rid="bib45">Pardoll, 2012</xref>). As a still emerging yet quite compelling immunotherapy approach in contemporary cancer medicine, targeting of immune checkpoints is being extensively investigated in ongoing and upcoming clinical trials aimed at unleashing T cell activity, augmenting immune recognition against tumor metastases, and boosting immune memory for long-lasting clinical remission post-treatment (<xref ref-type="bibr" rid="bib50">Postow et al., 2015</xref>; <xref ref-type="bibr" rid="bib40">Le et al., 2017</xref>). While the remarkable potential for checkpoint inhibitors in treating cancer is unequivocally exciting, the combined clinical trial experience has shown that durable effective treatment outcomes occur only in a limited subset of patients (<xref ref-type="bibr" rid="bib58">Sharma et al., 2017</xref>). Alas, some cancer types are presumed to be minimally immunogenic, resulting in little or no response to this treatment strategy (<xref ref-type="bibr" rid="bib5">Brahmer et al., 2012</xref>). An accumulating body of evidence has established that certain immunological features, including T cell exhaustion (e.g., Tim-3) and exclusion (<xref ref-type="bibr" rid="bib34">Jerby-Arnon et al., 2018</xref>), senescence markers (<xref ref-type="bibr" rid="bib43">Moreira et al., 2019</xref>) such as CD57, or immune incompetence, exhaustion, or premature senescence (e.g., loss of CD27) (<xref ref-type="bibr" rid="bib52">Riaz et al., 2017</xref>; <xref ref-type="bibr" rid="bib65">Vallejo, 2005</xref>), could perhaps reflect or even predict sensitivity and resistance to checkpoint inhibitor-based cancer immunotherapy. However, early attempts at identification of specific pathological biomarkers to predict immunotherapy response, including transcriptomic rubrics (<xref ref-type="bibr" rid="bib3">Auslander et al., 2018</xref>), machine learning algorithms (<xref ref-type="bibr" rid="bib35">Johannet et al., 2021</xref>), genomic approaches (<xref ref-type="bibr" rid="bib13">Cormedi et al., 2021</xref>) such as tumor mutational burden (<xref ref-type="bibr" rid="bib21">Duffy and Crown, 2019</xref>), among others (<xref ref-type="bibr" rid="bib49">Pilard et al., 2021</xref>), have thus far shown somewhat inconsistent results, challenged further by the inherent molecular, cellular, and biophysical diversity of human tumors (<xref ref-type="bibr" rid="bib62">Teng et al., 2015</xref>; <xref ref-type="bibr" rid="bib64">Tumeh et al., 2014</xref>; <xref ref-type="bibr" rid="bib12">Carbognin et al., 2015</xref>). Instead, most currently applied parameters merely document tumor responses that have already occurred as opposed to predicting it a priori; these include the standard Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 (<xref ref-type="bibr" rid="bib22">Eisenhauer et al., 2009</xref>) and even the newer proposed response assessment rubrics specific for immunotherapy (iRECIST). Considering the sheer complexity of the biological interactions between the immune system and the tumor microenvironment, one could reason that the introduction of more sophisticated mathematical analytic techniques would hopefully have potential to enhance the qualitative and quantitative understanding of such interactions and to improve malignant tumor treatment with checkpoint inhibitors, ultimately supporting the development of a predictive clinical tool that could either minimize or overcome this clear unmet need of cancer medicine.</p><p>In previous work, mechanistic mathematical models of immunomodulatory interventions for cancer control utilizing coupled ordinary differential equations (ODEs) have already allowed the prediction of tumor response after Bacillus Calmette–Guérin (BCG) administration in superficial transitional cell carcinoma of the urinary bladder and the serum prostate-specific antigen response after prostate cancer vaccine administration with considerable accuracy (<xref ref-type="bibr" rid="bib9">Bunimovich-Mendrazitsky et al., 2016</xref>; <xref ref-type="bibr" rid="bib8">Bunimovich-Mendrazitsky et al., 2007</xref>; <xref ref-type="bibr" rid="bib38">Kronik et al., 2010</xref>). Moreover, other investigators have shown that mechanistic models of interleukin-21 (IL-21) therapy schedules based on tumor mass and antigenic properties can predict growth patterns of multiple tumor types in patients receiving personalized doses of IL-21 (<xref ref-type="bibr" rid="bib16">de Pillis et al., 2005</xref>). In another notable work, mathematical modeling of neoantigen fitness based on cancer population evolution and antigen recognition potential was able to predict tumor response and patient survival following treatment with checkpoint blockade therapy, as validated in both melanoma patients treated with anti-CTLA4 and in lung cancer patients treated with anti-PD-1 therapies (<xref ref-type="bibr" rid="bib41">Łuksza et al., 2017</xref>). Finally, modeling of chemotherapy and targeted drug therapy by our group with similar mathematical techniques was able to accurately reproduce entire dose–response curves of tumor cell kill with untargeted cytotoxic and ligand-directed agents (<xref ref-type="bibr" rid="bib47">Pascal et al., 2013a</xref>; <xref ref-type="bibr" rid="bib32">Hosoya et al., 2016</xref>; <xref ref-type="bibr" rid="bib17">Dogra et al., 2018</xref>; <xref ref-type="bibr" rid="bib26">Goel et al., 2019</xref>; <xref ref-type="bibr" rid="bib20">Dogra et al., 2020b</xref>). These examples highlight the previous success of mathematical models to qualitatively or quantitatively discern the underlying biologically and physically relevant, often nonlinear processes present in cancer, which may otherwise be missed, and help optimize treatment delivery approaches.</p><p>The innovation and scope of the present study is to demonstrate how standard clinical measures, including radiological imaging assessments and immunohistochemical (IHC) analysis of tissue samples, may inform a mechanistic mathematical model to elucidate patient and tumor-specific attributes that would likely benefit from the application of checkpoint inhibitor-based therapy. Our model parameters, which can be determined in multiple ways (e.g., from early time point imaging and/or histopathology data), present a clear advantage over the standard measures currently used in the clinic for predicting treatment outcome and patient survival. The mathematical model presented in this report is based on an extensive series of prior methodological reports (<xref ref-type="bibr" rid="bib47">Pascal et al., 2013a</xref>; <xref ref-type="bibr" rid="bib32">Hosoya et al., 2016</xref>; <xref ref-type="bibr" rid="bib17">Dogra et al., 2018</xref>; <xref ref-type="bibr" rid="bib26">Goel et al., 2019</xref>; <xref ref-type="bibr" rid="bib20">Dogra et al., 2020b</xref>; <xref ref-type="bibr" rid="bib15">Das et al., 2013</xref>; <xref ref-type="bibr" rid="bib48">Pascal et al., 2013b</xref>; <xref ref-type="bibr" rid="bib67">Wang et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Koay et al., 2014</xref>; <xref ref-type="bibr" rid="bib24">Frieboes et al., 2015</xref>; <xref ref-type="bibr" rid="bib66">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib6">Brocato et al., 2018</xref>; <xref ref-type="bibr" rid="bib14">Cristini et al., 2017</xref>; <xref ref-type="bibr" rid="bib18">Dogra et al., 2019</xref>; <xref ref-type="bibr" rid="bib7">Brocato et al., 2019</xref>; <xref ref-type="bibr" rid="bib19">Dogra et al., 2020a</xref>; <xref ref-type="bibr" rid="bib27">Goel et al., 2020</xref>; <xref ref-type="bibr" rid="bib1">Anaya et al., 2021</xref>), but with rigorous emphasis on parameters related to the cancer-immune response to the treatment with checkpoint inhibitors in the setting of patients with solid tumors. In particular, we have developed a model that contains key mechanistic biological and physical processes involved in checkpoint inhibitor therapy, which has been objectively validated against imaging data of patient tumor burden and measured response, defined by both change in total tumor burden and patient survival (<xref ref-type="bibr" rid="bib10">Butner et al., 2020</xref>). To date, this modeling work has only examined tumor response on a bulk scale, without confirming the mechanistic links between key model parameters and the underlying biology they describe. In this work, we demonstrate how model parameters may be informed by using cell-scale IHC analysis of biopsied tissues, which are available as early as at the start of treatment, for reliable prediction of therapeutic response. Thus, this represents a key step towards clinical translation (i) by validating prior results in additional patient cohorts and (ii) demonstrating how IHC may be used with the model to predict patient response at times closer to the start of treatment. The predictions obtained through this model were compared against available retrospective clinical data from published trials with monoclonal antibodies blocking the PD-1/PD-L1 pathway for validation, thereby focusing on a quantitative relationship between tumor response and its underlying mechanisms. Taken together, these retrospective results indicate that our predictive mathematical model with the class of PD-1/PD-L1 checkpoint inhibitors has translational merit and that it should therefore be evaluated as an integral predictive biomarker in the setting of carefully designed prospective cancer investigational trials.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2-1"><title>Mathematical model</title><p>The final mathematical model we used for comparison with clinical data is a single ODE, which determines changes in relative tumor mass over time after initiation of anti-PD-1 therapy. It is a simplified and user-friendly version originated from a complex set of partial differential equations (PDEs), which takes into account spatial relationships within the tumor microenvironment. By reducing the model to this closed-form solution, we present the model in a form that combines related biological processes (see <xref ref-type="fig" rid="fig1">Figure 1</xref>) into only a few easy-to-interpret values, while also ensuring the ability to obtain unique solutions when only minimal data are available. The full mathematical derivation has been demonstrated elsewhere (<xref ref-type="bibr" rid="bib10">Butner et al., 2020</xref>) and also in Appendix 1, but its underlying cancer biology is also schematically depicted in <xref ref-type="fig" rid="fig1">Figure 1</xref>. It is ultimately represented by<disp-formula id="equ1">, <label>(1)</label><mml:math id="m1"><mml:msup><mml:mrow><mml:mi>ρ</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>ρ</mml:mi></mml:mrow><mml:mrow><mml:mi>∞</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>ρ</mml:mi></mml:mrow><mml:mrow><mml:mi>∞</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mi>α</mml:mi><mml:mo>-</mml:mo><mml:mi>μ</mml:mi><mml:mo>+</mml:mo><mml:mi>μ</mml:mi><mml:mo>⋅</mml:mo><mml:mi>Λ</mml:mi></mml:mrow></mml:mfenced><mml:mo>⋅</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:math></disp-formula></p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Schematic representation of biological mechanisms included in the mathematical model.</title><p>These processes are described by four partial differential equations, which are solved to obtain Equation (1). Briefly, the checkpoint inhibitor enters the tumor via diffusion (D<sub>a</sub>) leading to time-dependent drug concentration (σ), which then binds to the conjugate receptor on immune cells at rate λ. Immune cells (ψ<sub>k</sub>) are drawn into the tumor microenvironment via cytokine-mediated chemotaxis (χ), resulting in immune checkpoint inhibitor-mediated cancer cell kill at rate λ<sub>p</sub>. The full mathematical model derivation and its underlying assumptions are provided in a recent modeling and analysis report (<xref ref-type="bibr" rid="bib10">Butner et al., 2020</xref>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70130-fig1-v2.tif"/></fig><p>where <italic>ρ′</italic> is the normalized tumor mass, <italic>t</italic> is time, <italic>α</italic> is a proliferation constant of tumor cells, <italic>Λ</italic> is the ratio of cancer cells (<italic>σ</italic>) to effector immune cells multiplied by the ability of immune cells (<italic>ψ</italic><sub>k</sub>) to kill cancer cells (namely, the anti-tumor immune state), <italic>µ</italic> is the effect of immunotherapy on the ability of immune cells to kill cancer cells, and <inline-formula><mml:math id="inf1"><mml:msub><mml:mrow><mml:mi>ρ</mml:mi></mml:mrow><mml:mrow><mml:mi>∞</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> represents the final long-term tumor burden, which may be calculated as<disp-formula id="equ2"><label>(2)</label><mml:math id="m2"><mml:msub><mml:mrow><mml:mi>ρ</mml:mi></mml:mrow><mml:mrow><mml:mi>∞</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>α</mml:mi><mml:mo>-</mml:mo><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi>μ</mml:mi><mml:mo>⋅</mml:mo><mml:mi>Λ</mml:mi></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>In words, <xref ref-type="disp-formula" rid="equ1">Equation (1)</xref> describes the time-course tumor burden under immunotherapy intervention as a function of three key parameters <italic>α, Λ</italic>, and <italic>µ</italic>, which represent the ability of malignant tumor cells to grow, the ability of immune cells to kill cancer cells within the tumor environment, and the potential efficacy of checkpoint inhibitor-based immunotherapy treatment. <xref ref-type="disp-formula" rid="equ2">Equation (2)</xref> states that long-term tumor burden is a function of the relationship between tumor growth and kill rates [the greater of which sets the sign of response, i.e., progressive disease (<inline-formula><mml:math id="inf2"><mml:mi>α</mml:mi><mml:mo>§amp;gt;</mml:mo><mml:mi>μ</mml:mi></mml:math></inline-formula>) or favorable clinical response (<inline-formula><mml:math id="inf3"><mml:mi>α</mml:mi><mml:mo>§amp;lt;</mml:mo><mml:mi>μ</mml:mi></mml:math></inline-formula>)], as scaled by the parameter <inline-formula><mml:math id="inf4"><mml:mi>μ</mml:mi><mml:mo>⋅</mml:mo><mml:mi>Λ</mml:mi></mml:math></inline-formula>. These three parameters are intrinsically abstract terms, which have multiple components in themselves. <italic>Λ</italic> is dependent on the density of malignant tumor versus immune cells at the initiation of immunotherapy (<italic>t</italic> = 0) and on the ability of each immune cell to kill tumor cells. <xref ref-type="disp-formula" rid="equ1">Equation (1)</xref> assumes the following five assumptions: (i) tumor mass grows exponentially with rate <italic>α</italic> in the absence of immune cell killing; (ii) cancer cells are killed by one type of net effector immune cell (termed <inline-formula><mml:math id="inf5"><mml:mi>ψ</mml:mi></mml:math></inline-formula><sub>k</sub>); (iii) the influx of immune cells and the concentration of checkpoint inhibitor within the tumor environment reaches a drug steady state on time scales far faster (i.e., from hours to days) than clinical response (i.e., from weeks to months); (iv) all cancer cells are within an average intratumoral movement path length of effector immune cells, and the effect of cytokines in stimulating immune cell function/movement is small, thus spatial diversity effects are negligible in this particular case; and (v) the site of action of the checkpoint inhibitor takes place at the interface between the tumor cell and immune cell, with blocking of one of the immune checkpoint receptors, either on the cancer or on the immune cell, which are deemed necessary and sufficient for blockade of the immune inhibitory pathway.</p><p>While one must recognize that although these assumptions certainly represent a gross biological generalization of the true tumor-immune microenvironment complexity, they enable direct comparison with clinical response data, in which measurements of all the parameters required for a full description of immune system reaction to tumors are often not readily available in conventional clinical settings. In this retrospective mechanistic analysis, we start with a simple biophysical model to validate clinical findings and the mechanistic links between high-level model parameters and the underlying biology they describe, with the possible addition of further refining variables as an aspirational goal for future prospective translational or clinical cancer studies. The mathematical simulations and procedures conducted are fully described in Appendix 1 (<xref ref-type="fig" rid="app1fig1">Appendix 1—figures 1</xref> and <xref ref-type="fig" rid="app1fig2">2</xref>); finally, we also address the implications of these arbitrary choices in ‘Discussion’.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Clinical trials with checkpoint inhibitors used to fit the mathematical model and derived values of tumor proliferation constant, <italic>α</italic>.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reference</th><th align="left" valign="bottom">Tumor type histopathology</th><th align="left" valign="bottom">Checkpoint inhibitor monoclonal antibody</th><th align="left" valign="bottom">Constant<italic>α</italic> (days<sup>–1</sup>)</th><th align="left" valign="bottom">Calculated tumor doubling time (<italic>α</italic><sup>–1</sup>, days)</th></tr></thead><tbody><tr><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib39">Le et al., 2015</xref></td><td align="left" valign="bottom">CRC</td><td align="left" valign="bottom">Pembrolizumab (anti-PD1)</td><td align="char" char="." valign="bottom">0.0622</td><td align="char" char="." valign="bottom">11</td></tr><tr><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib51">Powles et al., 2014</xref></td><td align="left" valign="bottom">UCC</td><td align="left" valign="bottom">Atezolizumab (anti-PD-L1)</td><td align="char" char="." valign="bottom">0.016</td><td align="char" char="." valign="bottom">43</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib2">Antonia et al., 2015</xref></td><td align="left" valign="bottom">SCLC</td><td align="left" valign="bottom">Nivolumab (anti-PD1)</td><td align="char" char="." valign="bottom">0.014</td><td align="char" char="." valign="bottom">50</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib63">Topalian et al., 2012</xref></td><td align="left" valign="bottom">MM</td><td align="left" valign="bottom">Nivolumab (anti-PD1)</td><td align="char" char="." valign="bottom">0.0069</td><td align="char" char="." valign="bottom">100</td></tr><tr><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib4">Borghaei et al., 2015</xref></td><td align="left" valign="bottom">NSCLC</td><td align="left" valign="bottom">Nivolumab (anti-PD1)</td><td align="char" char="." valign="bottom">0.0069</td><td align="char" char="." valign="bottom">100</td></tr><tr><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib44">Motzer et al., 2015</xref></td><td align="left" valign="bottom">RCC</td><td align="left" valign="bottom">Nivolumab (anti-PD1)</td><td align="char" char="." valign="bottom">0.0034</td><td align="char" char="." valign="bottom">204</td></tr></tbody></table><table-wrap-foot><fn><p>CRC, colorectal carcinoma; UCC, urothelial cell carcinoma; SCLC, small cell lung cancer;MM, malignant melanoma; NSCLC, non-small lung cancer; RCC, renal cell carcinoma.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-2"><title>Clinical evaluation and fitting of the mathematical model</title><p>To evaluate <xref ref-type="disp-formula" rid="equ1">Equation (1)</xref> with clinical data, we initially focused on clinical trials with the class of checkpoint inhibitors that specifically target the PD-1/PD-L1 pathway. In this analysis, tumor volumes over time measurements were obtained from six published clinical trial reports (<xref ref-type="bibr" rid="bib4">Borghaei et al., 2015</xref>; <xref ref-type="bibr" rid="bib2">Antonia et al., 2015</xref>; <xref ref-type="bibr" rid="bib39">Le et al., 2015</xref>; <xref ref-type="bibr" rid="bib44">Motzer et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">Powles et al., 2014</xref>; <xref ref-type="bibr" rid="bib63">Topalian et al., 2012</xref>). As an initial retrospective proof of concept, five clinical trials of anti-PD-1 therapy plus another clinical trial of anti-PD-L1 treatment (<xref ref-type="table" rid="table1">Table 1</xref>) were included, with the combined dataset representing several common solid tumor pathology types (n = 189 cancer patients); this dataset represents our model calibration cohort. An online tool (Web Plot Digitizer [<xref ref-type="bibr" rid="bib56">Rohatgi, 2010</xref>]) served to extract the individual patient tumor response data over time from the published clinical trials, and subsequently <xref ref-type="disp-formula" rid="equ1">Equation (1)</xref> was fit to these individual and collective datasets to derive the parameters <italic>α</italic>, <italic>Λ</italic>, and <italic>µ</italic>. A unique fit (and thus set of parameter values) was obtained for the data from each individual patient, and more details on this procedure may also be found in <xref ref-type="bibr" rid="bib10">Butner et al., 2020</xref>.</p><p>The fitting procedure was performed in two sequential steps. First, the fastest progressing patient in each trial was fit to a simple exponential function to estimate <italic>α</italic> for each cancer histopathology (i.e., approximation for uninhibited tumor doubling time). Although this approximation represents a limiting factor in the study, it was necessary due to lack of pretreatment tumor measurement in the calibration cohort, which would allow for more accurate estimation of the growth kinetic without clinical intervention. As presented, <italic>α</italic> may represent the fastest tumor growth potential in the cohort and thus and overestimate the true average growth kinetic; however, because it likely represents the patient with the least response to treatment in each cohort, we take it to be a reasonable approximation of tumor growth kinetic unaffected by treatment. Second, this cancer-specific <italic>α</italic> was used to determine the remaining parameters, <italic>Λ</italic> and <italic>µ</italic>, for each individual patient by fitting <xref ref-type="disp-formula" rid="equ1">Equation (1)</xref> to time-course tumor burden data (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref>). The curve fitting was performed by using nonlinear least squares and the Mathematica function NonLinearModelFit (<xref ref-type="bibr" rid="bib70">Wolfram Research I, 2017</xref>). The workflow for deriving the model parameters from the clinical data is depicted in <xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref>.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Mathematical model fit to individual responses to immune checkpoint inhibition.</title><p>Open circles represent data points of clinical response in 10 patients extracted from <xref ref-type="bibr" rid="bib63">Topalian et al., 2012</xref>, while solid lines represent best curve fits of <xref ref-type="disp-formula" rid="equ1">Equation (1)</xref> to those data (with <italic>α</italic><sup>–1</sup> = 144 days). Each color represents a different patient. Immunotherapy was begun at <italic>t</italic> = 0, and tumor volume was designated as the relative change in volume from <italic>t</italic> = 0 (i.e., tumor volume of 1 at <italic>t</italic> = 0). The dashed line depicts the cutoff used for classifying patients deemed as responders (partial or complete response) versus nonresponders (stable disease or disease progression) according to the RECIST v1.1 criteria.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70130-fig2-v2.tif"/></fig><p>The results from this model calibration were checked against an additional validation patient cohort from the University of Texas M.D. Anderson Cancer Center (MDACC). Briefly, data from patients (n = 64) with non-small cell lung cancer (NSCLC) treated with pembrolizumab (MK-3475) were obtained from the investigational study NCT02444741 (a total of 95 patients were obtained; however, 18 left the study after admission, 11 were removed due to lack of pretreatment measurements, 1 was excluded because all indexed lesions were treated with XRT, and 1 discontinued treatment but continued follow-up). Serial lung tumor measurements were taken on post-contract chest CT images acquired with 2.5 mm slice thickness. All lesions that were previously indexed by the radiologist were included in order to best reproduce actual clinical practice (patients had a range of 1–12 indexed lesions; median, 3 indexed lesions). Lesion volumes were estimated as 3D spheres calculated from the geometric mean of long and short axes of each lesion at each follow-up, and then volumes were summed to generate a total volume for all indexed lesions at each follow-up time point. Because imaging data before the start of pembrolizumab treatment were available for each patient within this cohort, we were able to obtain a patient-specific pretreatment growth rate <italic>α</italic> for each patient between the imaging immediately preceding start of treatment and at the time of first immunotherapy treatment by using the exponential growth rate estimation <inline-formula><mml:math id="inf6"><mml:mi>ρ</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>≈</mml:mo><mml:msup><mml:mrow><mml:mtext>e</mml:mtext></mml:mrow><mml:mrow><mml:mi>α</mml:mi><mml:mo>∙</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> between tumor burdens measured via imaging collected before treatment and at start of treatment. These per-patient <italic>α</italic> values were then used in <xref ref-type="disp-formula" rid="equ1">Equation (1)</xref> to obtain values for <italic>Λ</italic> and <italic>µ</italic>, as described above.</p></sec><sec id="s2-3"><title>Sensitivity analysis and model simulations</title><p>A sensitivity analysis was next performed on <xref ref-type="disp-formula" rid="equ1">Equation (1)</xref> in two independent ways (<xref ref-type="fig" rid="app1fig2">Appendix 1—figure 2</xref>). First, each of the parameters <italic>Λ</italic> and <italic>µ</italic> were individually altered by ±10% while holding the other parameters constant to simulate the change in relative tumor mass (<inline-formula><mml:math id="inf7"><mml:mi>ρ</mml:mi><mml:mi>`</mml:mi></mml:math></inline-formula>). Second, individual values of <inline-formula><mml:math id="inf8"><mml:mi>ρ</mml:mi><mml:mi>`</mml:mi></mml:math></inline-formula> in the calibration cohort were varied by a uniform random variable by ±0.1 (i.e., 10%) and <xref ref-type="disp-formula" rid="equ1">Equation (1)</xref> was re-fitted to these modified data to determine any changes in the derived values for <italic>Λ</italic> and <italic>µ</italic>. To determine stability of derived <italic>Λ</italic> and <italic>µ</italic> values over time, we also truncated the <inline-formula><mml:math id="inf9"><mml:mi>ρ</mml:mi><mml:mi>`</mml:mi></mml:math></inline-formula> data at differing time points (namely, <italic>t</italic> &lt; 30, 60, 120, 200 days), and subsequently re-fitted <xref ref-type="disp-formula" rid="equ1">Equation (1)</xref> to these truncated data to determine <italic>Λ</italic> and <italic>µ</italic>. The correlation between the derived values of <italic>Λ</italic> and <italic>µ</italic> from the truncated datasets and the full composite dataset was then determined by using Spearman correlation analysis. A simulated long-term RECIST v1.1 score was then determined for each patient by projecting the expected tumor burden at <italic>t</italic> = 700 days (chosen as a time point beyond the last reported follow-up for most of the patients) by using these values of <italic>Λ</italic> and <italic>µ</italic> derived from the truncated fits in order to compare the predicted RECIST scores to the known retrospective scores. Finally, full model simulations were performed at different levels of <italic>α</italic>, <italic>Λ,</italic> and <italic>µ</italic> to determine values of <inline-formula><mml:math id="inf10"><mml:mi>ρ</mml:mi><mml:mi>`</mml:mi></mml:math></inline-formula> based on input parameter variation.</p></sec><sec id="s2-4"><title>Validation of <italic>Λ</italic> and <italic>µ</italic> by tumor-infiltrating immune cells and immunostaining</title><p>The parameters <italic>Λ</italic> and <italic>µ</italic> derived from fitting the clinical response data were compared to pathological biomarkers from additional anti-PD-1 or PD-L1 clinical trials (<xref ref-type="bibr" rid="bib4">Borghaei et al., 2015</xref>; <xref ref-type="bibr" rid="bib55">Robert et al., 2015b</xref>; <xref ref-type="bibr" rid="bib5">Brahmer et al., 2012</xref>; <xref ref-type="bibr" rid="bib64">Tumeh et al., 2014</xref>; <xref ref-type="bibr" rid="bib44">Motzer et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">Powles et al., 2014</xref>; <xref ref-type="bibr" rid="bib63">Topalian et al., 2012</xref>; <xref ref-type="bibr" rid="bib25">Garon et al., 2015</xref>; <xref ref-type="bibr" rid="bib31">Herbst et al., 2014</xref>; <xref ref-type="bibr" rid="bib36">Kefford et al., 2014</xref>; <xref ref-type="bibr" rid="bib59">Spira et al., 2015</xref>; <xref ref-type="bibr" rid="bib61">Taube et al., 2014</xref>; <xref ref-type="bibr" rid="bib68">Weber et al., 2015</xref>), as shown in <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>. Specifically, we investigated the ability of <italic>Λ</italic> and <italic>µ</italic> to correlate with CD8+ tumor-infiltrating lymphocytes (TILs) and tumor PD-L1 expression, respectively. To compare the values of <italic>Λ</italic> and <italic>µ</italic> derived from fitting the clinical response data over time with the trials assessing TILs and PD-L1 expression, the extracted cancer patients were categorized into objective responders versus nonresponders by applying RECIST v1.1 (<xref ref-type="bibr" rid="bib22">Eisenhauer et al., 2009</xref>) note that resist categories determined by lesion diameter (<italic>D</italic>) or our volume estimation are mathematically comparable by <inline-formula><mml:math id="inf11"><mml:mi>V</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:mfrac><mml:mi>π</mml:mi><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula> . Specifically, patients from all RECIST categories (<xref ref-type="bibr" rid="bib22">Eisenhauer et al., 2009</xref>) were condensed into two groups for analysis, with patients who had ≥30% reduction in tumor burden (partial or complete response) grouped into the ‘favorable’ response group, and patients with either &lt;30% disease reduction (stable disease or disease progression) into the ‘unfavorable’ response group. The last recorded time point from the response curve from each individual patient served to designate the RECIST v1.1 category as this provides the most accurate long-term treatment outcome.</p><p>After stratifying each patient into a RECIST v1.1 category, <italic>Λ</italic> and <italic>µ</italic> were compared between responding and nonresponding patients by using a Wilcoxon rank sum test and compared to the literature either as a continuous variable (<italic>Λ</italic>) or by using thresholds (<italic>µ</italic>). For comparison with biomarkers reported in the literature, <italic>Λ</italic> was converted to an estimated intratumoral CD8+ T cell count (for details, the interested reader is referred to <xref ref-type="bibr" rid="bib10">Butner et al., 2020</xref>) by assuming each CD8+ T cell would kill one tumor cell on average (the assumed mean ‘fitness’ of the immune cell population [<xref ref-type="bibr" rid="bib42">Mempel and Bauer, 2008</xref>]), and that there were 5558 cells/mm<sup>2</sup> in the tumor microenvironment, as has been quantitatively measured in melanoma (<xref ref-type="bibr" rid="bib23">Erdag et al., 2012</xref>). For comparison with PD-L1 staining, <italic>µ</italic> was converted from its raw numerical value to a percentage; no other scaling of the variable was performed as the number of cancer cells bound by anti-PD-1/PD-L1 therapy action is the dominant term in the integral specified in Equation S4 in <xref ref-type="bibr" rid="bib10">Butner et al., 2020</xref>; this approximation and its implications are further examined in ‘Discussion.’ Assessment of objective response rates (ORRs) at standard thresholds of 1% and 5% PD-L1 staining (corresponding to <italic>µ</italic>) were used in this study. Other alternative PD-L1 cutoffs present in some studies (<xref ref-type="table" rid="table1">Table 1</xref> and <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>) were not included in this analysis due to the relatively small numbers of patients. The biomarker trials used for validation of these parameters are also presented in <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Quantification of model parameters <italic>α</italic>, <italic>Λ,</italic> and <italic>µ</italic></title><p>Measured tumor burden data over time from the total collective calibration patient pool (n = 189) after initiating checkpoint inhibitor-based therapy were extracted from the six reported clinical trials (<xref ref-type="table" rid="table1">Table 1</xref>). Of this population, 55 patients (29%) had objective responses by RECIST v1.1 criteria while 134 patients (71%) demonstrated stable/progressive disease. The derived tumor proliferation constant, <italic>α</italic>, was determined to range from 0.0034 (tumor doubling time of ~200 days) in renal cell carcinoma to 0.0622 (tumor doubling time of ~11 days) in non-mismatch repair colon cancer with an average α of 0.018 and average tumor doubling time of ~85 days (<xref ref-type="table" rid="table1">Table 1</xref>). In the validation NSCLC cohort, 25 patients (39%) had objective response, and 39 patients (61%) demonstrated stable/progressive disease, with individual patient proliferation constants (<italic>α</italic>) ranging from –0.0129 to 0.0602 (note that <italic>α</italic> &lt; 0 indicates a subset of patients that had a shrinking tumor burden before start of therapy).</p><p>Having determined <italic>α</italic> for each cancer histopathology, the clinical response curves to checkpoint inhibitors for each tumor type were fit to <xref ref-type="disp-formula" rid="equ1">Equation (1)</xref> to determine <italic>Λ</italic> and <italic>µ</italic>. The average root-mean-square error of fitting <xref ref-type="disp-formula" rid="equ1">Equation (1)</xref> to the clinical data was only 0.4%. A sample exponential fit to extracted melanoma time-course data is shown (<xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref>, second panel, red curve). A sample of these curve fits for patients with melanoma from the trial by <xref ref-type="bibr" rid="bib63">Topalian et al., 2012</xref> is depicted in <xref ref-type="fig" rid="fig2">Figure 2</xref>. The derived fits from all 189 patient response curves in the calibration cohort yielded a mean ± standard error of the mean (SEM) value of <italic>Λ</italic> of 0.714 ± 0.257 in patients with partial/complete response and 0.0995 ± 0.0264 in patients with stable/progressive disease (p=0.119; Wilcoxon two-tail), while the mean ± SEM value of <italic>µ</italic> was 0.054 ± 0.014 versus 0.013 ± 0.0012 in partial/complete response versus stable/progressive disease, respectively (p&lt;0.001). In the validation NSCLC cohort, the mean ± SEM value of <italic>Λ</italic> was 0.876 ± 0.102 in patients with partial/complete response and 0.0297 ± 0.469 in patients with stable/progressive disease (p&lt;0.001), while the mean ± SEM value of <italic>µ</italic> was 0.0529 ± 0.00982 to –0.0064 ± 0.0032 in partial/complete response versus stable/progressive disease (p&lt;0.001). These values are depicted in <xref ref-type="fig" rid="fig3">Figure 3</xref>. These results suggest that, while <italic>Λ</italic> and <italic>µ</italic> give significantly separated classification ranges for partial/complete response versus stable/progressive disease, the specific value of the binary classification threshold is likely a function of the unique disease-drug combination used, as observed in our prior studies (<xref ref-type="bibr" rid="bib11">Butner et al., 2021</xref>). This point was explored further through a ‘leave-one-cancer-type-out’ validation study within the calibration cohort, wherein one cancer type was removed from the calibration cohort and used as validation against the parameter ranges in the reduced calibration set obtained from <xref ref-type="bibr" rid="bib4">Borghaei et al., 2015</xref>; <xref ref-type="bibr" rid="bib2">Antonia et al., 2015</xref>; <xref ref-type="bibr" rid="bib39">Le et al., 2015</xref>; <xref ref-type="bibr" rid="bib44">Motzer et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">Powles et al., 2014</xref>; and <xref ref-type="bibr" rid="bib63">Topalian et al., 2012</xref>. Results revealed that mean ranges vary between individual cancer types, and that <italic>μ</italic> shows more consistent significant difference between response categories relative to <italic>Λ</italic> (these results are consistent with the results shown in <xref ref-type="bibr" rid="bib10">Butner et al., 2020</xref>; these results are shown in <xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3</xref>, <xref ref-type="supplementary-material" rid="app1fig3sdata1">Appendix 1—figure 3—source data 1</xref>, and explored further in ‘Discussion’).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Depiction of average <italic>Λ</italic> and <italic>μ</italic> values in patients with response (n = 55) versus nonresponse (n = 134) in the calibration cohort (circular markers), while n = 25 patients had objective response and 39 patients demonstrated stable/progressive disease in the validation cohort (square markers) as determined by RECIST v1.1 criteria.</title><p>Open markers represent the average values of patients with response, and solid markers represent patients with stable/progressive disease. Error bars represent the standard error of the mean (SEM). p-Values of separation between groups by Wilcoxon rank sum (two tails): <italic>Λ</italic>, p=0.119 and p&lt;0.001 for literature (calibration) and non-small cell lung cancer (NSCLC) (validation) cohorts, respectively; <italic>μ</italic>, p&lt;0.001 for both literature (calibration) and NSCLC (validation) cohorts. Insets: receiver-operator characteristic (ROC) curves for patient response versus model parameters for both cohorts; <italic>Λ</italic>, literature cohort: sensitivity = 0.381, specificity = 0.945, accuracy = 545; <italic>μ</italic>, literature cohort: sensitivity = 0.891, specificity = 0.567, accuracy = 0.661; <italic>Λ</italic>, NSCLC clinical cohort: sensitivity = 0.600, specificity = 0.744, accuracy = 0.688; <italic>μ</italic>, NSCLC clinical cohort: sensitivity = 0.960, specificity = 0.769, accuracy = 0.844. PR, partial response; CR, complete response. Examples of cancer drug-specific parameter values may be found in <xref ref-type="bibr" rid="bib10">Butner et al., 2020</xref>.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Numerical data for <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70130-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70130-fig3-v2.tif"/></fig></sec><sec id="s3-2"><title>Confirmation of model stability</title><p>The parameters <italic>α</italic>, <italic>Λ,</italic> and <italic>µ</italic> were held constant during the sensitivity analysis at three different values for each parameter. These values were the minimum, average, and maximum values derived from fitting <xref ref-type="disp-formula" rid="equ1">Equation (1)</xref> to the data as described above. Changing <italic>Λ</italic> and <italic>µ</italic> from these values ± 10% yielded a maximum change in <inline-formula><mml:math id="inf12"><mml:mi>ρ</mml:mi><mml:mi>`</mml:mi></mml:math></inline-formula> of 9.2% at <italic>t</italic> = 200 days. Varying <inline-formula><mml:math id="inf13"><mml:msup><mml:mrow><mml:mi>ρ</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> data points randomly up to ±0.1 resulted in Spearman correlation coefficients of 0.766 and 0.919 for <italic>Λ</italic> and <italic>µ</italic>, respectively, derived from fitting these randomized data versus the actual clinical data. We note that, due to high stability observed to these perturbations in the large calibration cohort (n = 189 patients), we did not repeat this sensitivity analysis in the validation cohort. <italic>Λ</italic> values derived from fitting truncated <inline-formula><mml:math id="inf14"><mml:mi>ρ</mml:mi><mml:mi>`</mml:mi></mml:math></inline-formula> data for the calibration cohort at various time points displayed Spearman correlation coefficients with <italic>Λ</italic> derived from fitting the full data ranging from 0.071 at <italic>t</italic> &lt; 30 days to 0.730 at <italic>t</italic> &lt; 200 days, while Spearman correlation coefficients for <italic>µ</italic> ranged from 0.910 (<italic>t</italic> &lt; 30 days) to 0.921 (<italic>t</italic> &lt; 200 days) for all truncated datasets (<xref ref-type="table" rid="table2">Table 2</xref>). In the validation cohort, Spearman correlation coefficients for <italic>Λ</italic> ranged 0.800 at <italic>t</italic> &lt; 30 days to 0.771 at <italic>t</italic> &lt; 200 days, and 0.800 at <italic>t</italic> &lt; 30 days to 0.989 at <italic>t</italic> &lt; 200 days for <italic>μ</italic>. Simulated RECIST v1.1 categorization (complete/partial response vs. stable/progressive disease) by using the values of <italic>Λ</italic> and <italic>µ</italic> derived from fitting the truncated calibration cohort data resulted in 19% misclassification by using data from <italic>t</italic> &lt; 60 days (n = 177) and 13% misclassification at <italic>t</italic> &lt; 200 days (n = 189) when compared to the full dataset. In the validation cohort, we observed 18.6% misclassification at <italic>t</italic> &lt; 60 days (n = 43) and 10.9% misclassification at <italic>t</italic> &lt;200 days (n = 64). Predicted normalized tumor mass after initiation of immunotherapy is depicted at different combinations of <italic>α</italic>, <italic>Λ,</italic> and <italic>µ</italic> (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Spearman correlation coefficients between <italic>Λ</italic> and <italic>µ</italic> derived from fitting truncated datasets versus full dataset.</title><p><italic>t</italic>: days. Note that values of 1.000 are due to only a small number of patients (n = 4) that were imaged before <italic>t</italic> = 30 days in the validation cohort; these either did not have lesion volumes reassessed before the next reported time threshold (<italic>t</italic> = 60 days) or did not observe a change in monotonic relationships within this timeframe (<italic>t</italic> = 30–120 days).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" colspan="4" valign="bottom">Calibration cohort</th><th align="left" valign="bottom"/><th align="left" colspan="4" valign="bottom">Validation cohort</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic><bold>Λ</bold></italic></td><td align="left" valign="bottom"><italic><bold>t</bold></italic> <bold>&lt; 60</bold></td><td align="left" valign="bottom"><italic><bold>t</bold></italic> <bold>&lt; 120</bold></td><td align="left" valign="bottom"><italic><bold>t</bold></italic> <bold>&lt; 200</bold></td><td align="left" valign="bottom"><italic><bold>t</bold></italic> <bold>= all days</bold></td><td align="left" valign="bottom"><italic><bold>Λ</bold></italic></td><td align="left" valign="bottom"><italic><bold>t</bold></italic> <bold>&lt; 60</bold></td><td align="left" valign="bottom"><italic><bold>t</bold></italic> <bold>&lt; 120</bold></td><td align="left" valign="bottom"><italic><bold>t</bold></italic> <bold>&lt; 200</bold></td><td align="left" valign="bottom"><italic><bold>t</bold></italic> <bold>= all days</bold></td></tr><tr><td align="left" valign="bottom"><italic>t</italic> &lt; 30</td><td align="char" char="." valign="bottom">0.476</td><td align="char" char="." valign="bottom">0.162</td><td align="char" char="." valign="bottom">0.080</td><td align="char" char="." valign="bottom">0.071</td><td align="left" valign="bottom"><italic>t</italic> &lt; 30</td><td align="char" char="." valign="bottom">1.000</td><td align="char" char="." valign="bottom">1.000</td><td align="char" char="." valign="bottom">0.800</td><td align="char" char="." valign="bottom">0.800</td></tr><tr><td align="left" valign="bottom"><italic>t</italic> &lt; 60</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">0.416</td><td align="char" char="." valign="bottom">0.309</td><td align="char" char="." valign="bottom">0.306</td><td align="left" valign="bottom"><italic>t</italic> &lt; 60</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">0.812</td><td align="char" char="." valign="bottom">0.658</td><td align="char" char="." valign="bottom">0.823</td></tr><tr><td align="left" valign="bottom"><italic>t</italic> &lt; 120</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">0.668</td><td align="char" char="." valign="bottom">0.599</td><td align="left" valign="bottom"><italic>t</italic> &lt; 120</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">0.676</td><td align="char" char="." valign="bottom">0.750</td></tr><tr><td align="left" valign="bottom"><italic>t</italic> &lt; 200</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">0.730</td><td align="left" valign="bottom"><italic>t</italic> &lt; 200</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">0.771</td></tr><tr><td align="left" valign="bottom"><italic><bold>µ</bold></italic></td><td align="left" valign="bottom"><italic><bold>t</bold></italic> <bold>&lt; 60</bold></td><td align="left" valign="bottom"><italic><bold>t</bold></italic> <bold>&lt; 120</bold></td><td align="left" valign="bottom"><italic><bold>t</bold></italic> <bold>&lt; 200</bold></td><td align="left" valign="bottom"><italic><bold>t</bold></italic> <bold>= all days</bold></td><td align="left" valign="bottom"><italic><bold>µ</bold></italic></td><td align="left" valign="bottom"><italic><bold>t</bold></italic> <bold>&lt; 60</bold></td><td align="left" valign="bottom"><italic><bold>t</bold></italic> <bold>&lt; 120</bold></td><td align="left" valign="bottom"><italic><bold>t</bold></italic> <bold>&lt; 200</bold></td><td align="left" valign="bottom"><italic><bold>t</bold></italic> <bold>= all days</bold></td></tr><tr><td align="left" valign="bottom"><italic>t</italic> &lt; 30</td><td align="char" char="." valign="bottom">0.942</td><td align="char" char="." valign="bottom">0.928</td><td align="char" char="." valign="bottom">0.922</td><td align="char" char="." valign="bottom">0.910</td><td align="left" valign="bottom"><italic>t</italic> &lt; 30</td><td align="char" char="." valign="bottom">1.000</td><td align="char" char="." valign="bottom">0.800</td><td align="char" char="." valign="bottom">0.800</td><td align="char" char="." valign="bottom">0.800</td></tr><tr><td align="left" valign="bottom"><italic>t</italic> &lt; 60</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">0.968</td><td align="char" char="." valign="bottom">0.941</td><td align="char" char="." valign="bottom">0.946</td><td align="left" valign="bottom"><italic>t</italic> &lt; 60</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">0.974</td><td align="char" char="." valign="bottom">0.960</td><td align="char" char="." valign="bottom">0.963</td></tr><tr><td align="left" valign="bottom"><italic>t</italic> &lt; 120</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">0.946</td><td align="char" char="." valign="bottom">0.922</td><td align="left" valign="bottom"><italic>t</italic> &lt; 120</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">0.971</td><td align="char" char="." valign="bottom">0.961</td></tr><tr><td align="left" valign="bottom"><italic>t</italic> &lt; 200</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">0.921</td><td align="left" valign="bottom"><italic>t</italic> &lt; 200</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">0.989</td></tr></tbody></table></table-wrap><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Simulated response to immune checkpoint inhibition at different values of <italic>α</italic>, <italic>Λ,</italic> and <italic>µ</italic>.</title><p>Data are obtained from <xref ref-type="disp-formula" rid="equ1">Equation (1)</xref>. Normalized tumor volume (<inline-formula><mml:math id="inf15"><mml:mi>ρ</mml:mi><mml:mi>`</mml:mi></mml:math></inline-formula>) was determined at <italic>t</italic> = 200 days. Three different <italic>α</italic> values were used that represent the minimum, average, and maximum values derived from fitting the calibration cohort, as described in the text. <italic>Λ</italic> and <italic>µ</italic> were varied continuously over their respective ranges. Colors also correspond with <inline-formula><mml:math id="inf16"><mml:mi>ρ</mml:mi><mml:mi>`</mml:mi></mml:math></inline-formula> as per color map on the right. RECIST v1.1 criteria of response are listed to the right of the color bars.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70130-fig4-v2.tif"/></fig></sec><sec id="s3-3"><title>Analysis of model predictions</title><p>Using the binary classification of tumor response of partial/complete response as positive and stable/progressive disease as negative, receiver-operator characteristic (ROC) analysis was performed to identify optimal predictive response thresholds for <italic>μ</italic> and <italic>Λ</italic> (<xref ref-type="fig" rid="fig3">Figure 3</xref>, insets) as higher values of <italic>μ</italic> and <italic>Λ</italic> are expected to correspond to a more favorable patient response. Identification of optimal predictive thresholds in the calibration cohort by maximizing the Youden’s J statistic revealed cutoff thresholds where sensitivity (the proportion of correctly identified patients with partial/complete response) was higher for both <italic>Λ</italic> and <italic>μ</italic> (0.945 and 0.891, respectively), while specificity was reduced (0.381 for <italic>Λ</italic> and 0.567 <italic>μ</italic>). Response prediction thresholds were identified as 0.722 for <italic>Λ</italic> and 0.00905 for <italic>μ</italic>. Testing these same response threshold values (identified in the calibration cohort) in the validation cohort revealed sensitivity of 0.6 for <italic>Λ</italic> and for 0.960 <italic>μ</italic>, and specificity of 0.743 for <italic>Λ</italic> and 0.769 for <italic>μ</italic> in the validation cohort. We found that, in the calibration cohort, positive predictive values (PPVs; the probability a patient will be a responder when the model predicts they will be a responder: 0.381 for <italic>Λ</italic> and 0.458 for <italic>μ</italic>) were lower than the negative predictive values (NPVs; 0.889 for <italic>Λ</italic> and 0.927 for <italic>μ</italic>), indicating fewer false-negatives (stable/progressive disease) than false-positives (partial/complete response). This trend was confirmed in the validation cohort (a PPV of 0.600 for <italic>Λ</italic> and 0.723 for <italic>μ</italic>; an NPV of 0.744 for <italic>Λ</italic> and 0.968 for <italic>μ</italic>). Lastly, we note that overall accuracy was lower by both <italic>Λ</italic> and <italic>μ</italic> in the calibration cohort than were observed in the validation cohort; this is presumably due to the misbalance of patients with ORR (29% = 55 patients) versus patients with stable/progressive disease (71%, = 134 patients) while sensitivity (correctly identified patients with ORR) was higher than specificity.</p></sec><sec id="s3-4"><title>Comparison of <italic>Λ</italic> and <italic>µ</italic> with clinical and pathological data</title><p>Conversion of <italic>Λ</italic> to an estimated intratumoral CD8+ T cell count yielded a predicted mean ± SEM of 3970 ± 1429 cells/mm<sup>2</sup> in patients with partial/complete response to checkpoint inhibition and 553 ± 147 cells/mm<sup>2</sup> in patients with stable/progressive disease (<xref ref-type="fig" rid="fig5">Figure 5</xref>) in the calibration cohort, and 4871 ± 567 cells/mm<sup>2</sup> versus 165 ± 2,604 cells/mm<sup>2</sup> in patients with partial/complete response versus stable/progressive disease in the validation cohort. Intratumoral CD8+ T cell counts referenced from <xref ref-type="bibr" rid="bib64">Tumeh et al., 2014</xref> are derived from two scenarios, either encompassing data in the pretreatment setting only (n = 46) or data including pathological CD8+ T cell counts encompassing both pretreatment and on treatment (n = 23). In the pretreatment setting, the average intratumoral CD8+ T cell count was 2632 ± 518 cells/mm<sup>2</sup> in patients with partial/complete response to checkpoint inhibitors and 322 ± 133 cells/mm<sup>2</sup> in patients demonstrating stable/progressive disease, while including on-treatment plus pretreatment data yielded an average of 3770 ± 675 cells/mm<sup>2</sup> in patients with partial/complete response and 501 ± 113 cells/mm<sup>2</sup> in patients with stable/progressive disease.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Comparison of intratumoral CD8+ T cell count and tumor PD-L1 staining derived from fitting the model to clinical data and values reported in the literature, as described in the text.</title><p>(<bold>A</bold>) Model intratumoral CD8+ T cell count (circles: calibration cohort, p=0.119 [Wilcoxon, two-tail]; squares: validation cohort, p&lt;0.001) was derived from <italic>Λ</italic> and literature CD8 intratumoral count was taken from immunohistochemical (IHC) staining in <xref ref-type="bibr" rid="bib64">Tumeh et al., 2014</xref> in melanoma (diamonds; average CD8 counts including on-treatment values [n = 23]). CD8+ T cell counts from pretreatment biopsies only (n = 46) demonstrated mean values (± SEM) of 2632 ± 518 cells/mm<sup>2</sup> in patients with response to immunotherapy and 322 ± 133 cells/mm<sup>2</sup> in nonresponding patients, respectively. Values for CD8+ T cell counts are plotted as averages with error bars representing the standard error. (<bold>B</bold>) Patient response rates to immunotherapy stratified by PD-L1 staining were derived from <italic>µ</italic> from the model (calibration: red; validation: blue) and from references (<xref ref-type="bibr" rid="bib4">Borghaei et al., 2015</xref>; <xref ref-type="bibr" rid="bib55">Robert et al., 2015b</xref>; <xref ref-type="bibr" rid="bib5">Brahmer et al., 2012</xref>; <xref ref-type="bibr" rid="bib64">Tumeh et al., 2014</xref>; <xref ref-type="bibr" rid="bib44">Motzer et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">Powles et al., 2014</xref>; <xref ref-type="bibr" rid="bib63">Topalian et al., 2012</xref>; <xref ref-type="bibr" rid="bib25">Garon et al., 2015</xref>; <xref ref-type="bibr" rid="bib31">Herbst et al., 2014</xref>; <xref ref-type="bibr" rid="bib36">Kefford et al., 2014</xref>; <xref ref-type="bibr" rid="bib59">Spira et al., 2015</xref>; <xref ref-type="bibr" rid="bib61">Taube et al., 2014</xref>; <xref ref-type="bibr" rid="bib68">Weber et al., 2015</xref>) for the literature data (green; n = 975 for 1% cutoff, n = 1492 for 5% cutoff; see <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>). Response to immune checkpoint inhibition was determined by RECIST v1.1 criteria. PR, partial response; CR, complete response.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Numerical data for <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70130-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70130-fig5-v2.tif"/></fig><p>For comparison of <italic>µ</italic> with PD-L1 staining, data were extracted from a total of 12 published clinical trials (n = 975 cancer patients) with data on clinical response by using a PD-L1 staining cutoff of ≥1% versus &lt;1% and 1492 patients with a cutoff of ≥5% versus &lt;5%. The ORR of patients with these thresholds was 15% for PD-L1 staining &lt;1% and 28% for PD-L1 staining ≥1%, and 21% and 38% for &lt;5% and ≥5%, respectively. The ORR of patients in the calibration cohort by using the same thresholds in the derived values of <italic>µ</italic> was therefore 10% and 45% for patients with <italic>µ</italic> &lt; 1% and ≥1%, respectively, and was 25% and 67% for patients with <italic>µ</italic> &lt; 5% and ≥5%, while in the validation cohort, the model-predicted ORR was 9% and 71% for patients with <italic>µ</italic> &lt; 1% and ≥1%, respectively, and was 29% and 100% for patients with <italic>µ</italic> &lt; 5% and ≥5% (<xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>).</p></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>The translational mathematical model introduced here retrospectively investigates the molecular, cellular, and biophysical mechanism(s) behind patient response to immune checkpoint inhibitor therapy, and it explores the potential clinical value of the early prediction of treatment effectiveness. The reductionist approach introduced here simplifies the rather complex biological cross-talk between the immune system with cancer cells to a set of differential equations ultimately dependent on three intrinsic parameters that represent tumor proliferation, intratumoral immune cell presence/killing efficiency (considered as baseline immune cell infiltration), and checkpoint inhibition efficacy; this latter parameter represents the active role of the checkpoint inhibitors in initiating and amplifying the anti-tumor response. We have demonstrated that these parameters may be informed using either imaging or IHC measures, enabling for robust implementation even when some of these measures are unavailable, and offering methods to calculate PD-L1 density and intratumoral CD8+ T cell counts without invasive methods or to inform the model using only IHC measures at start of treatment.</p><p>From a mechanistic standpoint, the mathematical model is fully compatible with the current understanding of the biological effect of checkpoint blockade and clinical subtypes of immunotherapy-responsive tumors (<xref ref-type="bibr" rid="bib62">Teng et al., 2015</xref>). First, the parameter values derived from our model for intratumoral immune cell infiltration (<italic>Λ</italic>) and immunotherapy antibody efficacy (<italic>µ</italic>) correspond with the quantitative pathological measures of intratumoral CD8+ T cell infiltration and PD-L1-positive staining (<xref ref-type="fig" rid="fig4">Figure 4</xref>; <xref ref-type="fig" rid="fig5">Figure 5</xref>). Although parameters <italic>Λ</italic> and <italic>μ</italic> are not direct representations of CD8+ T cell counts or PD-L1 expression, they correlated with measured pathological biomarkers, thus providing strong experimental evidence that these mathematical parameters may be quantified from these biomarkers. This offers a unique method for clinical translation using clinically available measured quantities to provide personalized prediction of patient response, a potential that we have often found particularly lacking in prior mechanistic modeling research. By demonstrating links between model parameters and known biology, our model may also be used to quantify the associated mechanistic underpinnings of treatment failure, with the goal of suggesting clinical interventions that may overcome these deficiencies to improve patient outcome. Unfortunately, the absence of per-patient measurements of CD8+ T cell counts or PD-L1 expression corresponding to individual patient response to treatment in the cohorts examined prevented analysis of how these parameters perform on a per-patient basis. We are currently collecting in-house a new dataset containing both measures for single patients, and the results of this study will be published once complete. We are also investigating how these biomarkers may inform the model to prospectively identify pseudoprogression (a clinical phenomenon wherein lesions are observed to experience rapid volume increase followed by disease response) on a per-patient basis, based on our previous result that retrospectively known long-term parameter values are unique in pseudoprogression (<xref ref-type="bibr" rid="bib10">Butner et al., 2020</xref>).</p><p>Moreover, the model demonstrates that the rate of immunotherapy response arises from nonlinear interactions between both adequate effector immune cell infiltration in tumors and immunotherapy efficacy within the tumor microenvironment (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Mechanistic mathematical modeling across several cancer types (<xref ref-type="table" rid="table1">Table 1</xref>) suggests that the overlying master equation [i.e., <xref ref-type="disp-formula" rid="equ1">Equation (1)</xref>] may well be universally applied, while the model parameter values presented here are likely tumor-specific. Indeed, this conclusion may be observed in <xref ref-type="fig" rid="fig3">Figure 3</xref>, where <italic>Λ</italic> and <italic>µ</italic> are distinctly different for ORR versus stable or progressive disease, but the values are different for the different cohorts, thereby capturing mechanistic differences across the different cancer types. However, further testing of the model in additional cancer types and larger patient cohorts remains necessary, in part due to the heterogeneous nature of solid tumors, both within individual patients and across different cancer types. The nontrivial interaction of these inputs predicted by this model is different in comparison to many established and current candidate biomarker studies (which focus on linear immunotherapy responses to just one of these markers, e.g., PD-L1 expression [<xref ref-type="bibr" rid="bib12">Carbognin et al., 2015</xref>]), perhaps providing a plausible explanation why single biomarkers sometimes provide inconsistent predictions across multiple cancer types (<xref ref-type="bibr" rid="bib12">Carbognin et al., 2015</xref>). Similarly, the unique insights presented herein allow for a more direct comparison of the model parameters to common pathological markers either reported in the literature or as yet to be reported, and provide a different perspective compared to other immune checkpoint inhibitor modeling studies (<xref ref-type="bibr" rid="bib41">Łuksza et al., 2017</xref>; <xref ref-type="bibr" rid="bib69">Wilkie and Hahnfeldt, 2013</xref>; <xref ref-type="bibr" rid="bib57">Serre et al., 2016</xref>).</p><p>The high sensitivity at early time points (<italic>t</italic> &lt; 60 days) demonstrated here indicates that this model may provide valuable early identification of cancer patients most likely to benefit from checkpoint inhibition therapy, with a high NPV indicating minimal false-negatives in the group predicted to receive the least benefit from therapy. Therefore, this attribute could serve as an early indicator of the efficacy of checkpoint inhibition by simply using either clinical or imaging measurements of index tumor lesions and by applying the mathematical model to project maximal effect for an individual patient. Further, the model demonstrates robustness and stability in the derived values of <italic>Λ</italic> and <italic>μ</italic> to random variations in <inline-formula><mml:math id="inf17"><mml:mi>ρ</mml:mi><mml:mi>`</mml:mi></mml:math></inline-formula>, and by using values of <italic>Λ</italic> and <italic>μ</italic> derived from fitting limited data over time (<xref ref-type="table" rid="table2">Table 2</xref>). This result is in stark contrast to previous mathematical descriptions of immune-mediated killing of cancer cells, where a relatively small change in a single input parameter of merely ±1% could dramatically vary tumor response by up to ±50% (<xref ref-type="bibr" rid="bib16">de Pillis et al., 2005</xref>).</p><p>Towards clinical translation of cancer models, a mathematical model with two simple terms (an exponential growth term and a regression term) has previously been used to successfully correlate and predict patient survival (<xref ref-type="bibr" rid="bib60">Stein et al., 2008</xref>). The fundamental difference between this prior model (<xref ref-type="bibr" rid="bib60">Stein et al., 2008</xref>) and the model reported here is that the quantification of cell death is more mechanistic, that is, depending on the specific mechanisms (<xref ref-type="fig" rid="fig1">Figure 1</xref>) that underlie cancer cell and immunotherapy drug interactions, hence allowing one to gain more mechanistic insight into the treatment system. As demonstrated, model parameters <italic>Λ</italic> and <italic>µ</italic> can be used to stratify responding and nonresponding patients (<xref ref-type="fig" rid="fig3">Figure 3</xref>), which has immediate potential utility as a biomarker for patient selection in prospective clinical trials. Moreover, the model contains biological values that, at least in principle, may either be measured (e.g., tumor burden, growth rate) or changed clinically (<italic>µ</italic>: e.g., drug dosing or dosing schedule; <inline-formula><mml:math id="inf18"><mml:mi>Λ</mml:mi></mml:math></inline-formula>: e.g., radiotherapy-induced increase in PD-L1 expression, radiotherapy abscopal effect). Thus, we expect that the model (i) may be informed by using standard-of-care measurements (e.g., <xref ref-type="fig" rid="fig5">Figure 5</xref>) and (ii) can provide quantitative information on which parameters must be changed to maximize therapeutic benefit, providing clinicians with potentially valuable decision-making information.</p><p>Of course, as with any biomathematical model, this model is based on several educated assumptions about the interactions of immune effectors (CD8+ T cells) with cancer cells, which naturally does not reflect the sheer magnitude and complexity of the tumor-immune microenvironment. These include the presence of immunosuppressive cells (such as neutrophils, myeloid-derived suppressor cells, Treg, and M2-polarized tumor-associated macrophages), which extensively infiltrate into tumor mass and hinder the efficacy of immune checkpoint inhibitors (<xref ref-type="bibr" rid="bib33">Jenkins et al., 2018</xref>). Moreover, effects of other immune cells, such as CD4+ T cells, are not explicitly included in the current model form; while it is likely that some of the effects from these other cells are captured within the model representation of CD8+ T cells, this assumption warrants future model development where each immune component is explicitly represented. Some of these assumptions (e.g., lack of immune cell/antibody infiltration terms) are supported with in vitro or in vivo data such as high rates of immune cell binding by anti-PD1 antibodies in the peripheral circulation (<xref ref-type="bibr" rid="bib63">Topalian et al., 2012</xref>) and local intratumoral (as opposed to systemic myelogenous) expansion of CD8+ T cells during checkpoint inhibition (<xref ref-type="bibr" rid="bib64">Tumeh et al., 2014</xref>; <xref ref-type="bibr" rid="bib53">Ribas et al., 2016</xref>). Other potential model parameters would logistically be quite challenging to measure in an outpatient clinic-ready setting routinely at this time, and their inclusion remains open for follow-up confirmatory retrospective studies and ultimately for future prospective clinical trials. As such, the integration of additional prognostic biomarkers and master regulators that intrinsically (e.g., genetic stability) and extrinsically control the efficacy of immunotherapy represents open research areas for future translational investigation.</p><p>Moreover, the two response parameters derived from the model, <italic>Λ</italic> and <italic>μ</italic>, represent abstract terms, which may not precisely model intratumoral CD8+ lymphocyte infiltration and tumor cell PD-L1 staining and potentially can be modified by relevant determinants, such as tumor mutational burden (<xref ref-type="bibr" rid="bib28">Goodman et al., 2017</xref>) or the human microbiome of the gut (<xref ref-type="bibr" rid="bib29">Gopalakrishnan et al., 2018</xref>). Moreover, these parameters represent a simplifying average value of these fluctuating parameters. We take this to be a reasonable assumption because (i) these quantities are not directly measurable (this is also the case for cell proliferation events underlying the tumor growth rate parameter <italic>α</italic>), (ii) in our in-house data, times between patient reassessment ranged 17–91 days, so even direct measurement of these would provide an average value over this time period, and (iii) these processes take place at far shorter times than patient reassessments. By presenting the model in this reduced form, we enable simplified interpretation of the results while also providing a single, easy-to-understand scalar that contains significant information about the treatment response.</p><p>Finally, a few operational aspects of this work deserve further comment. Response was defined using RECIST v1.1 criteria, <italic>in lieu</italic> of the more recent adaptation of RECIST criteria to immunotherapy treatment (iRECIST), because the studies used to derive the model parameters in this mechanistic analysis did not incorporate these new criteria, and our use of published data for the calibration cohort limited or precluded us from obtaining a priori knowledge about nontarget lesions. Moreover, our work to date has only involved testing our model in a handful of cancer types, and further validation in additional disease phenotypes and larger total patient populations remains outstanding. These inherent study limitations notwithstanding, we will continue to improve our model to more accurately predict outcomes in the immunotherapy-specific setting of individualized cancer patients, potentially through the inclusion of additional biomarkers, as bioactive molecules such as IFNγ, CD206, CX3CR1, CD1D, and iNOS, along with cell-mediated mechanisms known to have an effect on immune checkpoint inhibitor therapy (<xref ref-type="bibr" rid="bib46">Park et al., 2018</xref>; <xref ref-type="bibr" rid="bib30">Gubin et al., 2018</xref>). However, we do not anticipate that such improvements and refinements would change the basic findings and the potential value of the mechanistic mathematical model reported in this work. In going forward, one hopes that knowledge broadly applicable across multiple cancer types and/or immune microenvironment control will be serially incorporated to the dynamic model upon their future discovery and validation.</p><p>In conclusion, we present a mechanistic model of immune checkpoint inhibition that is able to describe various immunotherapy response profiles, with the inputs to the model correlating with common pathological biomarkers in current clinical use. An early and robust a priori predictor for checkpoint inhibition response and outcome might provide a glimpse of the immense potential for timely adjustments and therapeutic personalization. Future prospective investigations of this computational science-assisted approach will focus on readily available clinical data as inputs to the model and further refining the complex interplay between the immune system and the cancer environment to extract other important variables for immunotherapy efficacy. Towards this end, we are currently pursuing in-house collection of per-patient, paired IHC measures of PD-L1 or T cell counts with tumor response, which will enable us to directly correlate IHC measures of interest with tumor response, while also allowing for examination of additional patient parameters, such as tumor stage or patient age. We will also obtain data from different cancer types known to be receptive to ICI therapy in order to further evaluate the potential of our model to perform as a more universal predictor across an even more diverse array of cancer phenotypes. Ultimately, the merit of this approach will rely on its future ability to reliably predict early individual patient response with the goal of improving personalized cancer care.</p></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>See COI form submitted</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Validation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Data curation, Investigation, Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con17"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Investigation, Methodology, Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con19"><p>Investigation, Methodology, Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con20"><p>Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing – original draft, Writing – review and editing, Data curation</p></fn><fn fn-type="con" id="con21"><p>Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Clinical trial registration NCT02444741.</p></fn><fn fn-type="other"><p>Human subjects: In-house patient cohort were obtained as de-identified data from a study conducted in accordance with the U.S. Common Rule and with Institutional Review Board Approval at MD Anderson (2014-1020), including waiver of informed consent. This work has been published in J Immunother Cancer. 2020; 8(2): e001001. PMC7555111. doi: 10.1136/jitc-2020-001001.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-70130-transrepform1-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>No new clinical patient data was produced in this study. Data used that was obtained from literature is available in the original publications; we have been careful to cite each of these in the manuscript. Interested researchers should reach out directly to the primary authors of these studies. Data for the in-house clinical trial cohort are from the study reported in PMC7555111; interested researchers should contact the authors of this publication with any data requests.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anaya</surname><given-names>DA</given-names></name><name><surname>Dogra</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Haider</surname><given-names>M</given-names></name><name><surname>Ehab</surname><given-names>J</given-names></name><name><surname>Jeong</surname><given-names>DK</given-names></name><name><surname>Ghayouri</surname><given-names>M</given-names></name><name><surname>Lauwers</surname><given-names>GY</given-names></name><name><surname>Thomas</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>R</given-names></name><name><surname>Butner</surname><given-names>JD</given-names></name><name><surname>Nizzero</surname><given-names>S</given-names></name><name><surname>Ramírez</surname><given-names>JR</given-names></name><name><surname>Plodinec</surname><given-names>M</given-names></name><name><surname>Sidman</surname><given-names>RL</given-names></name><name><surname>Cavenee</surname><given-names>WK</given-names></name><name><surname>Pasqualini</surname><given-names>R</given-names></name><name><surname>Arap</surname><given-names>W</given-names></name><name><surname>Fleming</surname><given-names>JB</given-names></name><name><surname>Cristini</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A Mathematical Model to Estimate Chemotherapy Concentration at the Tumor-Site and Predict Therapy Response in Colorectal Cancer Patients with Liver Metastases</article-title><source>Cancers</source><volume>13</volume><elocation-id>444</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13030444</pub-id><pub-id pub-id-type="pmid">33503971</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonia</surname><given-names>SJ</given-names></name><name><surname>Bendell</surname><given-names>JC</given-names></name><name><surname>Taylor</surname><given-names>MH</given-names></name><name><surname>Calvo</surname><given-names>E</given-names></name><name><surname>Jaeger</surname><given-names>D</given-names></name><name><surname>De Braud</surname><given-names>FG</given-names></name><name><surname>Ott</surname><given-names>PA</given-names></name><name><surname>Pietanza</surname><given-names>MC</given-names></name><name><surname>Horn</surname><given-names>L</given-names></name><name><surname>Le</surname><given-names>DT</given-names></name><name><surname>Morse</surname><given-names>M</given-names></name><name><surname>Lopez-Martin</surname><given-names>JA</given-names></name><name><surname>Ascierto</surname><given-names>PA</given-names></name><name><surname>Christensen</surname><given-names>O</given-names></name><name><surname>Grosso</surname><given-names>J</given-names></name><name><surname>Simon</surname><given-names>JS</given-names></name><name><surname>Lin</surname><given-names>CS</given-names></name><name><surname>Eder</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032</article-title><source>Journal of Clinical Oncology</source><volume>33</volume><elocation-id>7503</elocation-id><pub-id pub-id-type="doi">10.1200/jco.2015.33.15_suppl.7503</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auslander</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Frederick</surname><given-names>DT</given-names></name><name><surname>Miao</surname><given-names>B</given-names></name><name><surname>Moll</surname><given-names>T</given-names></name><name><surname>Tian</surname><given-names>T</given-names></name><name><surname>Wei</surname><given-names>Z</given-names></name><name><surname>Madan</surname><given-names>S</given-names></name><name><surname>Sullivan</surname><given-names>RJ</given-names></name><name><surname>Boland</surname><given-names>G</given-names></name><name><surname>Flaherty</surname><given-names>K</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name><name><surname>Ruppin</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma</article-title><source>Nature Medicine</source><volume>24</volume><fpage>1545</fpage><lpage>1549</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0157-9</pub-id><pub-id pub-id-type="pmid">30127394</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borghaei</surname><given-names>H</given-names></name><name><surname>Paz-Ares</surname><given-names>L</given-names></name><name><surname>Horn</surname><given-names>L</given-names></name><name><surname>Spigel</surname><given-names>DR</given-names></name><name><surname>Steins</surname><given-names>M</given-names></name><name><surname>Ready</surname><given-names>NE</given-names></name><name><surname>Chow</surname><given-names>LQ</given-names></name><name><surname>Vokes</surname><given-names>EE</given-names></name><name><surname>Felip</surname><given-names>E</given-names></name><name><surname>Holgado</surname><given-names>E</given-names></name><name><surname>Barlesi</surname><given-names>F</given-names></name><name><surname>Kohlhäufl</surname><given-names>M</given-names></name><name><surname>Arrieta</surname><given-names>O</given-names></name><name><surname>Burgio</surname><given-names>MA</given-names></name><name><surname>Fayette</surname><given-names>J</given-names></name><name><surname>Lena</surname><given-names>H</given-names></name><name><surname>Poddubskaya</surname><given-names>E</given-names></name><name><surname>Gerber</surname><given-names>DE</given-names></name><name><surname>Gettinger</surname><given-names>SN</given-names></name><name><surname>Rudin</surname><given-names>CM</given-names></name><name><surname>Rizvi</surname><given-names>N</given-names></name><name><surname>Crinò</surname><given-names>L</given-names></name><name><surname>Antonia</surname><given-names>SJ</given-names></name><name><surname>Dorange</surname><given-names>C</given-names></name><name><surname>Harbison</surname><given-names>CT</given-names></name><name><surname>Graf Finckenstein</surname><given-names>F</given-names></name><name><surname>Brahmer</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer</article-title><source>The New England Journal of Medicine</source><volume>373</volume><fpage>1627</fpage><lpage>1639</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1507643</pub-id><pub-id pub-id-type="pmid">26412456</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brahmer</surname><given-names>JR</given-names></name><name><surname>Tykodi</surname><given-names>SS</given-names></name><name><surname>Chow</surname><given-names>LQM</given-names></name><name><surname>Hwu</surname><given-names>W-J</given-names></name><name><surname>Topalian</surname><given-names>SL</given-names></name><name><surname>Hwu</surname><given-names>P</given-names></name><name><surname>Drake</surname><given-names>CG</given-names></name><name><surname>Camacho</surname><given-names>LH</given-names></name><name><surname>Kauh</surname><given-names>J</given-names></name><name><surname>Odunsi</surname><given-names>K</given-names></name><name><surname>Pitot</surname><given-names>HC</given-names></name><name><surname>Hamid</surname><given-names>O</given-names></name><name><surname>Bhatia</surname><given-names>S</given-names></name><name><surname>Martins</surname><given-names>R</given-names></name><name><surname>Eaton</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Salay</surname><given-names>TM</given-names></name><name><surname>Alaparthy</surname><given-names>S</given-names></name><name><surname>Grosso</surname><given-names>JF</given-names></name><name><surname>Korman</surname><given-names>AJ</given-names></name><name><surname>Parker</surname><given-names>SM</given-names></name><name><surname>Agrawal</surname><given-names>S</given-names></name><name><surname>Goldberg</surname><given-names>SM</given-names></name><name><surname>Pardoll</surname><given-names>DM</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Wigginton</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Safety and activity of anti-PD-L1 antibody in patients with advanced cancer</article-title><source>The New England Journal of Medicine</source><volume>366</volume><fpage>2455</fpage><lpage>2465</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1200694</pub-id><pub-id pub-id-type="pmid">22658128</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brocato</surname><given-names>TA</given-names></name><name><surname>Coker</surname><given-names>EN</given-names></name><name><surname>Durfee</surname><given-names>PN</given-names></name><name><surname>Lin</surname><given-names>Y-S</given-names></name><name><surname>Townson</surname><given-names>J</given-names></name><name><surname>Wyckoff</surname><given-names>EF</given-names></name><name><surname>Cristini</surname><given-names>V</given-names></name><name><surname>Brinker</surname><given-names>CJ</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Understanding the connection between nanoparticle uptake and cancer treatment efficacy using mathematical modeling</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>7538</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-25878-8</pub-id><pub-id pub-id-type="pmid">29795392</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brocato</surname><given-names>TA</given-names></name><name><surname>Brown-Glaberman</surname><given-names>U</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Selwyn</surname><given-names>RG</given-names></name><name><surname>Wilson</surname><given-names>CM</given-names></name><name><surname>Wyckoff</surname><given-names>EF</given-names></name><name><surname>Lomo</surname><given-names>LC</given-names></name><name><surname>Saline</surname><given-names>JL</given-names></name><name><surname>Hooda-Nehra</surname><given-names>A</given-names></name><name><surname>Pasqualini</surname><given-names>R</given-names></name><name><surname>Arap</surname><given-names>W</given-names></name><name><surname>Brinker</surname><given-names>CJ</given-names></name><name><surname>Cristini</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Predicting breast cancer response to neoadjuvant chemotherapy based on tumor vascular features in needle biopsies</article-title><source>JCI Insight</source><volume>4</volume><elocation-id>e126518</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.126518</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunimovich-Mendrazitsky</surname><given-names>S</given-names></name><name><surname>Shochat</surname><given-names>E</given-names></name><name><surname>Stone</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Mathematical model of BCG immunotherapy in superficial bladder cancer</article-title><source>Bulletin of Mathematical Biology</source><volume>69</volume><fpage>1847</fpage><lpage>1870</lpage><pub-id pub-id-type="doi">10.1007/s11538-007-9195-z</pub-id><pub-id pub-id-type="pmid">17457655</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunimovich-Mendrazitsky</surname><given-names>S</given-names></name><name><surname>Halachmi</surname><given-names>S</given-names></name><name><surname>Kronik</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Improving bacillus Calmette-Guérin (BCG) immunotherapy for bladder cancer by adding interleukin 2 (IL-2): A mathematical model</article-title><source>Mathematical Medicine and Biology</source><volume>33</volume><fpage>159</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1093/imammb/dqv007</pub-id><pub-id pub-id-type="pmid">25888550</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butner</surname><given-names>JD</given-names></name><name><surname>Elganainy</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>CX</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>SH</given-names></name><name><surname>Esnaola</surname><given-names>NF</given-names></name><name><surname>Pasqualini</surname><given-names>R</given-names></name><name><surname>Arap</surname><given-names>W</given-names></name><name><surname>Hong</surname><given-names>DS</given-names></name><name><surname>Welsh</surname><given-names>J</given-names></name><name><surname>Koay</surname><given-names>EJ</given-names></name><name><surname>Cristini</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy</article-title><source>Science Advances</source><volume>6</volume><elocation-id>eaay6298</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aay6298</pub-id><pub-id pub-id-type="pmid">32426472</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butner</surname><given-names>JD</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Elganainy</surname><given-names>D</given-names></name><name><surname>Al Feghali</surname><given-names>KA</given-names></name><name><surname>Plodinec</surname><given-names>M</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name><name><surname>Dogra</surname><given-names>P</given-names></name><name><surname>Nizzero</surname><given-names>S</given-names></name><name><surname>Ruiz-Ramirez</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>GV</given-names></name><name><surname>Tawbi</surname><given-names>HA</given-names></name><name><surname>Chung</surname><given-names>C</given-names></name><name><surname>Koay</surname><given-names>EJ</given-names></name><name><surname>Welsh</surname><given-names>JW</given-names></name><name><surname>Hong</surname><given-names>DS</given-names></name><name><surname>Cristini</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A mathematical model for the quantification of a patient’s sensitivity to checkpoint inhibitors and long-term tumour burden</article-title><source>Nature Biomedical Engineering</source><volume>5</volume><fpage>297</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1038/s41551-020-00662-0</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carbognin</surname><given-names>L</given-names></name><name><surname>Pilotto</surname><given-names>S</given-names></name><name><surname>Milella</surname><given-names>M</given-names></name><name><surname>Vaccaro</surname><given-names>V</given-names></name><name><surname>Brunelli</surname><given-names>M</given-names></name><name><surname>Caliò</surname><given-names>A</given-names></name><name><surname>Cuppone</surname><given-names>F</given-names></name><name><surname>Sperduti</surname><given-names>I</given-names></name><name><surname>Giannarelli</surname><given-names>D</given-names></name><name><surname>Chilosi</surname><given-names>M</given-names></name><name><surname>Bronte</surname><given-names>V</given-names></name><name><surname>Scarpa</surname><given-names>A</given-names></name><name><surname>Bria</surname><given-names>E</given-names></name><name><surname>Tortora</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): Sensitivity analysis of trials in melanoma, lung and genitourinary cancers</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0130142</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0130142</pub-id><pub-id pub-id-type="pmid">26086854</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cormedi</surname><given-names>MCV</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Colli</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Predicting immunotherapy response through genomics</article-title><source>Current Opinion in Genetics &amp; Development</source><volume>66</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.gde.2020.11.004</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cristini</surname><given-names>V</given-names></name><name><surname>Koay</surname><given-names>EJ</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2017">2017</year><chapter-title>An Introduction to Physical Oncology</chapter-title><person-group person-group-type="editor"><name><surname>Cristini</surname><given-names>V</given-names></name></person-group><source>An Introduction to Physical Oncology: How Mechanistic Mathematical Modeling Can Improve Cancer Therapy Outcomes</source><publisher-name>CRC Press, Taylor &amp; Francis Group</publisher-name><pub-id pub-id-type="doi">10.4324/9781315374499</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Niazi</surname><given-names>MKK</given-names></name><name><surname>Aggarwal</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Kanji</surname><given-names>S</given-names></name><name><surname>Das</surname><given-names>M</given-names></name><name><surname>Joseph</surname><given-names>M</given-names></name><name><surname>Gurcan</surname><given-names>M</given-names></name><name><surname>Cristini</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Impact of diffusion barriers to small cytotoxic molecules on the efficacy of immunotherapy in breast cancer</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e61398</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0061398</pub-id><pub-id pub-id-type="pmid">23620747</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Pillis</surname><given-names>LG</given-names></name><name><surname>Radunskaya</surname><given-names>AE</given-names></name><name><surname>Wiseman</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>A validated mathematical model of cell-mediated immune response to tumor growth</article-title><source>Cancer Research</source><volume>65</volume><fpage>7950</fpage><lpage>7958</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-0564</pub-id><pub-id pub-id-type="pmid">16140967</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dogra</surname><given-names>P</given-names></name><name><surname>Adolphi</surname><given-names>NL</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>Y-S</given-names></name><name><surname>Butler</surname><given-names>KS</given-names></name><name><surname>Durfee</surname><given-names>PN</given-names></name><name><surname>Croissant</surname><given-names>JG</given-names></name><name><surname>Noureddine</surname><given-names>A</given-names></name><name><surname>Coker</surname><given-names>EN</given-names></name><name><surname>Bearer</surname><given-names>EL</given-names></name><name><surname>Cristini</surname><given-names>V</given-names></name><name><surname>Brinker</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Establishing the effects of mesoporous silica nanoparticle properties on in vivo disposition using imaging-based pharmacokinetics</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>4551</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-06730-z</pub-id><pub-id pub-id-type="pmid">30382084</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dogra</surname><given-names>P</given-names></name><name><surname>Butner</surname><given-names>JD</given-names></name><name><surname>Chuang</surname><given-names>YL</given-names></name><name><surname>Caserta</surname><given-names>S</given-names></name><name><surname>Goel</surname><given-names>S</given-names></name><name><surname>Brinker</surname><given-names>CJ</given-names></name><name><surname>Cristini</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mathematical modeling in cancer nanomedicine: a review</article-title><source>Biomedical Microdevices</source><volume>21</volume><elocation-id>e380-2</elocation-id><pub-id pub-id-type="doi">10.1007/s10544-019-0380-2</pub-id><pub-id pub-id-type="pmid">30949850</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dogra</surname><given-names>P</given-names></name><name><surname>Butner</surname><given-names>JD</given-names></name><name><surname>Nizzero</surname><given-names>S</given-names></name><name><surname>Ruiz Ramírez</surname><given-names>J</given-names></name><name><surname>Noureddine</surname><given-names>A</given-names></name><name><surname>Peláez</surname><given-names>MJ</given-names></name><name><surname>Elganainy</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Le</surname><given-names>A-D</given-names></name><name><surname>Goel</surname><given-names>S</given-names></name><name><surname>Leong</surname><given-names>HS</given-names></name><name><surname>Koay</surname><given-names>EJ</given-names></name><name><surname>Brinker</surname><given-names>CJ</given-names></name><name><surname>Cristini</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Image-guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies</article-title><source>Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology</source><volume>12</volume><elocation-id>e1628</elocation-id><pub-id pub-id-type="doi">10.1002/wnan.1628</pub-id><pub-id pub-id-type="pmid">32314552</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dogra</surname><given-names>P</given-names></name><name><surname>Butner</surname><given-names>JD</given-names></name><name><surname>Ruiz Ramírez</surname><given-names>J</given-names></name><name><surname>Chuang</surname><given-names>Y-L</given-names></name><name><surname>Noureddine</surname><given-names>A</given-names></name><name><surname>Jeffrey Brinker</surname><given-names>C</given-names></name><name><surname>Cristini</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>A mathematical model to predict nanomedicine pharmacokinetics and tumor delivery</article-title><source>Computational and Structural Biotechnology Journal</source><volume>18</volume><fpage>518</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2020.02.014</pub-id><pub-id pub-id-type="pmid">32206211</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffy</surname><given-names>MJ</given-names></name><name><surname>Crown</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients</article-title><source>Clinical Chemistry</source><volume>65</volume><fpage>1228</fpage><lpage>1238</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2019.303644</pub-id><pub-id pub-id-type="pmid">31315901</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenhauer</surname><given-names>EA</given-names></name><name><surname>Therasse</surname><given-names>P</given-names></name><name><surname>Bogaerts</surname><given-names>J</given-names></name><name><surname>Schwartz</surname><given-names>LH</given-names></name><name><surname>Sargent</surname><given-names>D</given-names></name><name><surname>Ford</surname><given-names>R</given-names></name><name><surname>Dancey</surname><given-names>J</given-names></name><name><surname>Arbuck</surname><given-names>S</given-names></name><name><surname>Gwyther</surname><given-names>S</given-names></name><name><surname>Mooney</surname><given-names>M</given-names></name><name><surname>Rubinstein</surname><given-names>L</given-names></name><name><surname>Shankar</surname><given-names>L</given-names></name><name><surname>Dodd</surname><given-names>L</given-names></name><name><surname>Kaplan</surname><given-names>R</given-names></name><name><surname>Lacombe</surname><given-names>D</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)</article-title><source>European Journal of Cancer</source><volume>45</volume><fpage>228</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id><pub-id pub-id-type="pmid">19097774</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erdag</surname><given-names>G</given-names></name><name><surname>Schaefer</surname><given-names>JT</given-names></name><name><surname>Smolkin</surname><given-names>ME</given-names></name><name><surname>Deacon</surname><given-names>DH</given-names></name><name><surname>Shea</surname><given-names>SM</given-names></name><name><surname>Dengel</surname><given-names>LT</given-names></name><name><surname>Patterson</surname><given-names>JW</given-names></name><name><surname>Slingluff</surname><given-names>CL</given-names><suffix>Jr</suffix></name></person-group><year iso-8601-date="2012">2012</year><article-title>Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma</article-title><source>Cancer Research</source><volume>72</volume><fpage>1070</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-3218</pub-id><pub-id pub-id-type="pmid">22266112</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frieboes</surname><given-names>HB</given-names></name><name><surname>Smith</surname><given-names>BR</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Kotsuma</surname><given-names>M</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Day</surname><given-names>A</given-names></name><name><surname>Cahill</surname><given-names>B</given-names></name><name><surname>Flinders</surname><given-names>C</given-names></name><name><surname>Mumenthaler</surname><given-names>SM</given-names></name><name><surname>Mallick</surname><given-names>P</given-names></name><name><surname>Simbawa</surname><given-names>E</given-names></name><name><surname>AL-Fhaid</surname><given-names>AS</given-names></name><name><surname>Mahmoud</surname><given-names>SR</given-names></name><name><surname>Gambhir</surname><given-names>SS</given-names></name><name><surname>Cristini</surname><given-names>V</given-names></name><name><surname>Cinti</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Predictive modeling of drug response in non-Hodgkin’s lymphoma</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0129433</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0129433</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garon</surname><given-names>EB</given-names></name><name><surname>Rizvi</surname><given-names>NA</given-names></name><name><surname>Hui</surname><given-names>R</given-names></name><name><surname>Leighl</surname><given-names>N</given-names></name><name><surname>Balmanoukian</surname><given-names>AS</given-names></name><name><surname>Eder</surname><given-names>JP</given-names></name><name><surname>Patnaik</surname><given-names>A</given-names></name><name><surname>Aggarwal</surname><given-names>C</given-names></name><name><surname>Gubens</surname><given-names>M</given-names></name><name><surname>Horn</surname><given-names>L</given-names></name><name><surname>Carcereny</surname><given-names>E</given-names></name><name><surname>Ahn</surname><given-names>M-J</given-names></name><name><surname>Felip</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>J-S</given-names></name><name><surname>Hellmann</surname><given-names>MD</given-names></name><name><surname>Hamid</surname><given-names>O</given-names></name><name><surname>Goldman</surname><given-names>JW</given-names></name><name><surname>Soria</surname><given-names>J-C</given-names></name><name><surname>Dolled-Filhart</surname><given-names>M</given-names></name><name><surname>Rutledge</surname><given-names>RZ</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Lunceford</surname><given-names>JK</given-names></name><name><surname>Rangwala</surname><given-names>R</given-names></name><name><surname>Lubiniecki</surname><given-names>GM</given-names></name><name><surname>Roach</surname><given-names>C</given-names></name><name><surname>Emancipator</surname><given-names>K</given-names></name><name><surname>Gandhi</surname><given-names>L</given-names></name><collab>KEYNOTE-001 Investigators</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Pembrolizumab for the treatment of non-small-cell lung cancer</article-title><source>The New England Journal of Medicine</source><volume>372</volume><fpage>2018</fpage><lpage>2028</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1501824</pub-id><pub-id pub-id-type="pmid">25891174</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goel</surname><given-names>S</given-names></name><name><surname>Ferreira</surname><given-names>CA</given-names></name><name><surname>Dogra</surname><given-names>P</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Kutyreff</surname><given-names>CJ</given-names></name><name><surname>Siamof</surname><given-names>CM</given-names></name><name><surname>Engle</surname><given-names>JW</given-names></name><name><surname>Barnhart</surname><given-names>TE</given-names></name><name><surname>Cristini</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Size‐Optimized Ultrasmall Porous Silica Nanoparticles Depict Vasculature‐Based Differential Targeting in Triple Negative Breast Cancer</article-title><source>Small</source><volume>15</volume><elocation-id>1903747</elocation-id><pub-id pub-id-type="doi">10.1002/smll.201903747</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goel</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Dogra</surname><given-names>P</given-names></name><name><surname>Nizzero</surname><given-names>S</given-names></name><name><surname>Cristini</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Ferrari</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Sequential deconstruction of composite drug transport in metastatic breast cancer</article-title><source>Science Advances</source><volume>6</volume><elocation-id>26</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aba4498</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodman</surname><given-names>AM</given-names></name><name><surname>Kato</surname><given-names>S</given-names></name><name><surname>Bazhenova</surname><given-names>L</given-names></name><name><surname>Patel</surname><given-names>SP</given-names></name><name><surname>Frampton</surname><given-names>GM</given-names></name><name><surname>Miller</surname><given-names>V</given-names></name><name><surname>Stephens</surname><given-names>PJ</given-names></name><name><surname>Daniels</surname><given-names>GA</given-names></name><name><surname>Kurzrock</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers</article-title><source>Molecular Cancer Therapeutics</source><volume>16</volume><fpage>2598</fpage><lpage>2608</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-17-0386</pub-id><pub-id pub-id-type="pmid">28835386</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gopalakrishnan</surname><given-names>V</given-names></name><name><surname>Spencer</surname><given-names>CN</given-names></name><name><surname>Nezi</surname><given-names>L</given-names></name><name><surname>Reuben</surname><given-names>A</given-names></name><name><surname>Andrews</surname><given-names>MC</given-names></name><name><surname>Karpinets</surname><given-names>TV</given-names></name><name><surname>Prieto</surname><given-names>PA</given-names></name><name><surname>Vicente</surname><given-names>D</given-names></name><name><surname>Hoffman</surname><given-names>K</given-names></name><name><surname>Wei</surname><given-names>SC</given-names></name><name><surname>Cogdill</surname><given-names>AP</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Hudgens</surname><given-names>CW</given-names></name><name><surname>Hutchinson</surname><given-names>DS</given-names></name><name><surname>Manzo</surname><given-names>T</given-names></name><name><surname>Petaccia de Macedo</surname><given-names>M</given-names></name><name><surname>Cotechini</surname><given-names>T</given-names></name><name><surname>Kumar</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>WS</given-names></name><name><surname>Reddy</surname><given-names>SM</given-names></name><name><surname>Szczepaniak Sloane</surname><given-names>R</given-names></name><name><surname>Galloway-Pena</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>PL</given-names></name><name><surname>Shpall</surname><given-names>EJ</given-names></name><name><surname>Rezvani</surname><given-names>K</given-names></name><name><surname>Alousi</surname><given-names>AM</given-names></name><name><surname>Chemaly</surname><given-names>RF</given-names></name><name><surname>Shelburne</surname><given-names>S</given-names></name><name><surname>Vence</surname><given-names>LM</given-names></name><name><surname>Okhuysen</surname><given-names>PC</given-names></name><name><surname>Jensen</surname><given-names>VB</given-names></name><name><surname>Swennes</surname><given-names>AG</given-names></name><name><surname>McAllister</surname><given-names>F</given-names></name><name><surname>Marcelo Riquelme Sanchez</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Le Chatelier</surname><given-names>E</given-names></name><name><surname>Zitvogel</surname><given-names>L</given-names></name><name><surname>Pons</surname><given-names>N</given-names></name><name><surname>Austin-Breneman</surname><given-names>JL</given-names></name><name><surname>Haydu</surname><given-names>LE</given-names></name><name><surname>Burton</surname><given-names>EM</given-names></name><name><surname>Gardner</surname><given-names>JM</given-names></name><name><surname>Sirmans</surname><given-names>E</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Lazar</surname><given-names>AJ</given-names></name><name><surname>Tsujikawa</surname><given-names>T</given-names></name><name><surname>Diab</surname><given-names>A</given-names></name><name><surname>Tawbi</surname><given-names>H</given-names></name><name><surname>Glitza</surname><given-names>IC</given-names></name><name><surname>Hwu</surname><given-names>WJ</given-names></name><name><surname>Patel</surname><given-names>SP</given-names></name><name><surname>Woodman</surname><given-names>SE</given-names></name><name><surname>Amaria</surname><given-names>RN</given-names></name><name><surname>Davies</surname><given-names>MA</given-names></name><name><surname>Gershenwald</surname><given-names>JE</given-names></name><name><surname>Hwu</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Coussens</surname><given-names>LM</given-names></name><name><surname>Cooper</surname><given-names>ZA</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Daniel</surname><given-names>CR</given-names></name><name><surname>Ajami</surname><given-names>NJ</given-names></name><name><surname>Petrosino</surname><given-names>JF</given-names></name><name><surname>Tetzlaff</surname><given-names>MT</given-names></name><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name><name><surname>Jenq</surname><given-names>RR</given-names></name><name><surname>Wargo</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients</article-title><source>Science</source><volume>359</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1126/science.aan4236</pub-id><pub-id pub-id-type="pmid">29097493</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gubin</surname><given-names>MM</given-names></name><name><surname>Esaulova</surname><given-names>E</given-names></name><name><surname>Ward</surname><given-names>JP</given-names></name><name><surname>Malkova</surname><given-names>ON</given-names></name><name><surname>Runci</surname><given-names>D</given-names></name><name><surname>Wong</surname><given-names>P</given-names></name><name><surname>Noguchi</surname><given-names>T</given-names></name><name><surname>Arthur</surname><given-names>CD</given-names></name><name><surname>Meng</surname><given-names>W</given-names></name><name><surname>Alspach</surname><given-names>E</given-names></name><name><surname>Medrano</surname><given-names>RFV</given-names></name><name><surname>Fronick</surname><given-names>C</given-names></name><name><surname>Fehlings</surname><given-names>M</given-names></name><name><surname>Newell</surname><given-names>EW</given-names></name><name><surname>Fulton</surname><given-names>RS</given-names></name><name><surname>Sheehan</surname><given-names>KCF</given-names></name><name><surname>Oh</surname><given-names>ST</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name><name><surname>Artyomov</surname><given-names>MN</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy</article-title><source>Cell</source><volume>175</volume><elocation-id>1443</elocation-id><pub-id pub-id-type="doi">10.1016/j.cell.2018.11.003</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herbst</surname><given-names>RS</given-names></name><name><surname>Soria</surname><given-names>J-C</given-names></name><name><surname>Kowanetz</surname><given-names>M</given-names></name><name><surname>Fine</surname><given-names>GD</given-names></name><name><surname>Hamid</surname><given-names>O</given-names></name><name><surname>Gordon</surname><given-names>MS</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>McDermott</surname><given-names>DF</given-names></name><name><surname>Powderly</surname><given-names>JD</given-names></name><name><surname>Gettinger</surname><given-names>SN</given-names></name><name><surname>Kohrt</surname><given-names>HEK</given-names></name><name><surname>Horn</surname><given-names>L</given-names></name><name><surname>Lawrence</surname><given-names>DP</given-names></name><name><surname>Rost</surname><given-names>S</given-names></name><name><surname>Leabman</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Mokatrin</surname><given-names>A</given-names></name><name><surname>Koeppen</surname><given-names>H</given-names></name><name><surname>Hegde</surname><given-names>PS</given-names></name><name><surname>Mellman</surname><given-names>I</given-names></name><name><surname>Chen</surname><given-names>DS</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients</article-title><source>Nature</source><volume>515</volume><fpage>563</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1038/nature14011</pub-id><pub-id pub-id-type="pmid">25428504</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosoya</surname><given-names>H</given-names></name><name><surname>Dobroff</surname><given-names>AS</given-names></name><name><surname>Driessen</surname><given-names>WHP</given-names></name><name><surname>Cristini</surname><given-names>V</given-names></name><name><surname>Brinker</surname><given-names>LM</given-names></name><name><surname>Staquicini</surname><given-names>FI</given-names></name><name><surname>Cardó-Vila</surname><given-names>M</given-names></name><name><surname>D’Angelo</surname><given-names>S</given-names></name><name><surname>Ferrara</surname><given-names>F</given-names></name><name><surname>Proneth</surname><given-names>B</given-names></name><name><surname>Lin</surname><given-names>Y-S</given-names></name><name><surname>Dunphy</surname><given-names>DR</given-names></name><name><surname>Dogra</surname><given-names>P</given-names></name><name><surname>Melancon</surname><given-names>MP</given-names></name><name><surname>Stafford</surname><given-names>RJ</given-names></name><name><surname>Miyazono</surname><given-names>K</given-names></name><name><surname>Gelovani</surname><given-names>JG</given-names></name><name><surname>Kataoka</surname><given-names>K</given-names></name><name><surname>Brinker</surname><given-names>CJ</given-names></name><name><surname>Sidman</surname><given-names>RL</given-names></name><name><surname>Arap</surname><given-names>W</given-names></name><name><surname>Pasqualini</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release</article-title><source>PNAS</source><volume>113</volume><fpage>1877</fpage><lpage>1882</lpage><pub-id pub-id-type="doi">10.1073/pnas.1525796113</pub-id><pub-id pub-id-type="pmid">26839407</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>RW</given-names></name><name><surname>Barbie</surname><given-names>DA</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mechanisms of resistance to immune checkpoint inhibitors</article-title><source>British Journal of Cancer</source><volume>118</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1038/bjc.2017.434</pub-id><pub-id pub-id-type="pmid">29319049</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jerby-Arnon</surname><given-names>L</given-names></name><name><surname>Shah</surname><given-names>P</given-names></name><name><surname>Cuoco</surname><given-names>MS</given-names></name><name><surname>Rodman</surname><given-names>C</given-names></name><name><surname>Su</surname><given-names>M-J</given-names></name><name><surname>Melms</surname><given-names>JC</given-names></name><name><surname>Leeson</surname><given-names>R</given-names></name><name><surname>Kanodia</surname><given-names>A</given-names></name><name><surname>Mei</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>J-R</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Rabasha</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Margolais</surname><given-names>C</given-names></name><name><surname>Ashenberg</surname><given-names>O</given-names></name><name><surname>Ott</surname><given-names>PA</given-names></name><name><surname>Buchbinder</surname><given-names>EI</given-names></name><name><surname>Haq</surname><given-names>R</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Boland</surname><given-names>GM</given-names></name><name><surname>Sullivan</surname><given-names>RJ</given-names></name><name><surname>Frederick</surname><given-names>DT</given-names></name><name><surname>Miao</surname><given-names>B</given-names></name><name><surname>Moll</surname><given-names>T</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name><name><surname>Jenkins</surname><given-names>RW</given-names></name><name><surname>Thummalapalli</surname><given-names>R</given-names></name><name><surname>Kowalczyk</surname><given-names>MS</given-names></name><name><surname>Cañadas</surname><given-names>I</given-names></name><name><surname>Schilling</surname><given-names>B</given-names></name><name><surname>Cartwright</surname><given-names>ANR</given-names></name><name><surname>Luoma</surname><given-names>AM</given-names></name><name><surname>Malu</surname><given-names>S</given-names></name><name><surname>Hwu</surname><given-names>P</given-names></name><name><surname>Bernatchez</surname><given-names>C</given-names></name><name><surname>Forget</surname><given-names>M-A</given-names></name><name><surname>Barbie</surname><given-names>DA</given-names></name><name><surname>Shalek</surname><given-names>AK</given-names></name><name><surname>Tirosh</surname><given-names>I</given-names></name><name><surname>Sorger</surname><given-names>PK</given-names></name><name><surname>Wucherpfennig</surname><given-names>K</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Johnson</surname><given-names>BE</given-names></name><name><surname>Rotem</surname><given-names>A</given-names></name><name><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Yoon</surname><given-names>CH</given-names></name><name><surname>Izar</surname><given-names>B</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade</article-title><source>Cell</source><volume>175</volume><fpage>984</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.09.006</pub-id><pub-id pub-id-type="pmid">30388455</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johannet</surname><given-names>P</given-names></name><name><surname>Coudray</surname><given-names>N</given-names></name><name><surname>Donnelly</surname><given-names>DM</given-names></name><name><surname>Jour</surname><given-names>G</given-names></name><name><surname>Illa-Bochaca</surname><given-names>I</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Johnson</surname><given-names>DB</given-names></name><name><surname>Wheless</surname><given-names>L</given-names></name><name><surname>Patrinely</surname><given-names>JR</given-names></name><name><surname>Nomikou</surname><given-names>S</given-names></name><name><surname>Rimm</surname><given-names>DL</given-names></name><name><surname>Pavlick</surname><given-names>AC</given-names></name><name><surname>Weber</surname><given-names>JS</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Tsirigos</surname><given-names>A</given-names></name><name><surname>Osman</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma</article-title><source>Clinical Cancer Research</source><volume>27</volume><fpage>131</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-2415</pub-id><pub-id pub-id-type="pmid">33208341</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kefford</surname><given-names>R</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Hamid</surname><given-names>O</given-names></name><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Daud</surname><given-names>A</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Joshua</surname><given-names>AM</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Gangadhar</surname><given-names>TC</given-names></name><name><surname>Hersey</surname><given-names>P</given-names></name><name><surname>Weber</surname><given-names>JS</given-names></name><name><surname>Dronca</surname><given-names>RS</given-names></name><name><surname>Patnaik</surname><given-names>A</given-names></name><name><surname>Zarour</surname><given-names>HM</given-names></name><name><surname>Dolled-Filhart</surname><given-names>M</given-names></name><name><surname>Lunceford</surname><given-names>J</given-names></name><name><surname>Emancipator</surname><given-names>K</given-names></name><name><surname>Ebbinghaus</surname><given-names>S</given-names></name><name><surname>Kang</surname><given-names>SP</given-names></name><name><surname>Hwu</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475</article-title><source>Journal of Clinical Oncology</source><volume>32</volume><elocation-id>3005</elocation-id><pub-id pub-id-type="doi">10.1200/jco.2014.32.15_suppl.3005</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koay</surname><given-names>EJ</given-names></name><name><surname>Truty</surname><given-names>MJ</given-names></name><name><surname>Cristini</surname><given-names>V</given-names></name><name><surname>Thomas</surname><given-names>RM</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Chatterjee</surname><given-names>D</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Bhosale</surname><given-names>PR</given-names></name><name><surname>Tamm</surname><given-names>EP</given-names></name><name><surname>Crane</surname><given-names>CH</given-names></name><name><surname>Javle</surname><given-names>M</given-names></name><name><surname>Katz</surname><given-names>MH</given-names></name><name><surname>Gottumukkala</surname><given-names>VN</given-names></name><name><surname>Rozner</surname><given-names>MA</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Plunkett</surname><given-names>W</given-names></name><name><surname>Abbruzzese</surname><given-names>JL</given-names></name><name><surname>Wolff</surname><given-names>RA</given-names></name><name><surname>Varadhachary</surname><given-names>GR</given-names></name><name><surname>Ferrari</surname><given-names>M</given-names></name><name><surname>Fleming</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Transport properties of pancreatic cancer describe gemcitabine delivery and response</article-title><source>The Journal of Clinical Investigation</source><volume>124</volume><fpage>1525</fpage><lpage>1536</lpage><pub-id pub-id-type="doi">10.1172/JCI73455</pub-id><pub-id pub-id-type="pmid">24614108</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kronik</surname><given-names>N</given-names></name><name><surname>Kogan</surname><given-names>Y</given-names></name><name><surname>Elishmereni</surname><given-names>M</given-names></name><name><surname>Halevi-Tobias</surname><given-names>K</given-names></name><name><surname>Vuk-Pavlović</surname><given-names>S</given-names></name><name><surname>Agur</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models</article-title><source>PLOS ONE</source><volume>5</volume><elocation-id>12</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0015482</pub-id><pub-id pub-id-type="pmid">21151630</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>DT</given-names></name><name><surname>Uram</surname><given-names>JN</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Bartlett</surname><given-names>BR</given-names></name><name><surname>Kemberling</surname><given-names>H</given-names></name><name><surname>Eyring</surname><given-names>AD</given-names></name><name><surname>Skora</surname><given-names>AD</given-names></name><name><surname>Luber</surname><given-names>BS</given-names></name><name><surname>Azad</surname><given-names>NS</given-names></name><name><surname>Laheru</surname><given-names>D</given-names></name><name><surname>Biedrzycki</surname><given-names>B</given-names></name><name><surname>Donehower</surname><given-names>RC</given-names></name><name><surname>Zaheer</surname><given-names>A</given-names></name><name><surname>Fisher</surname><given-names>GA</given-names></name><name><surname>Crocenzi</surname><given-names>TS</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Duffy</surname><given-names>SM</given-names></name><name><surname>Goldberg</surname><given-names>RM</given-names></name><name><surname>de la Chapelle</surname><given-names>A</given-names></name><name><surname>Koshiji</surname><given-names>M</given-names></name><name><surname>Bhaijee</surname><given-names>F</given-names></name><name><surname>Huebner</surname><given-names>T</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Wood</surname><given-names>LD</given-names></name><name><surname>Cuka</surname><given-names>N</given-names></name><name><surname>Pardoll</surname><given-names>DM</given-names></name><name><surname>Papadopoulos</surname><given-names>N</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Cornish</surname><given-names>TC</given-names></name><name><surname>Taube</surname><given-names>JM</given-names></name><name><surname>Anders</surname><given-names>RA</given-names></name><name><surname>Eshleman</surname><given-names>JR</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Diaz</surname><given-names>LA</given-names><suffix>Jr</suffix></name></person-group><year iso-8601-date="2015">2015</year><article-title>PD-1 Blockade in tumors with mismatch-repair deficiency</article-title><source>The New England Journal of Medicine</source><volume>372</volume><fpage>2509</fpage><lpage>2520</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1500596</pub-id><pub-id pub-id-type="pmid">26028255</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>DT</given-names></name><name><surname>Durham</surname><given-names>JN</given-names></name><name><surname>Smith</surname><given-names>KN</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Bartlett</surname><given-names>BR</given-names></name><name><surname>Aulakh</surname><given-names>LK</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Kemberling</surname><given-names>H</given-names></name><name><surname>Wilt</surname><given-names>C</given-names></name><name><surname>Luber</surname><given-names>BS</given-names></name><name><surname>Wong</surname><given-names>F</given-names></name><name><surname>Azad</surname><given-names>NS</given-names></name><name><surname>Rucki</surname><given-names>AA</given-names></name><name><surname>Laheru</surname><given-names>D</given-names></name><name><surname>Donehower</surname><given-names>R</given-names></name><name><surname>Zaheer</surname><given-names>A</given-names></name><name><surname>Fisher</surname><given-names>GA</given-names></name><name><surname>Crocenzi</surname><given-names>TS</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Greten</surname><given-names>TF</given-names></name><name><surname>Duffy</surname><given-names>AG</given-names></name><name><surname>Ciombor</surname><given-names>KK</given-names></name><name><surname>Eyring</surname><given-names>AD</given-names></name><name><surname>Lam</surname><given-names>BH</given-names></name><name><surname>Joe</surname><given-names>A</given-names></name><name><surname>Kang</surname><given-names>SP</given-names></name><name><surname>Holdhoff</surname><given-names>M</given-names></name><name><surname>Danilova</surname><given-names>L</given-names></name><name><surname>Cope</surname><given-names>L</given-names></name><name><surname>Meyer</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Goldberg</surname><given-names>RM</given-names></name><name><surname>Armstrong</surname><given-names>DK</given-names></name><name><surname>Bever</surname><given-names>KM</given-names></name><name><surname>Fader</surname><given-names>AN</given-names></name><name><surname>Taube</surname><given-names>J</given-names></name><name><surname>Housseau</surname><given-names>F</given-names></name><name><surname>Spetzler</surname><given-names>D</given-names></name><name><surname>Xiao</surname><given-names>N</given-names></name><name><surname>Pardoll</surname><given-names>DM</given-names></name><name><surname>Papadopoulos</surname><given-names>N</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Eshleman</surname><given-names>JR</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Anders</surname><given-names>RA</given-names></name><name><surname>Diaz</surname><given-names>LA</given-names><suffix>Jr</suffix></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade</article-title><source>Science</source><volume>357</volume><fpage>409</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1126/science.aan6733</pub-id><pub-id pub-id-type="pmid">28596308</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Łuksza</surname><given-names>M</given-names></name><name><surname>Riaz</surname><given-names>N</given-names></name><name><surname>Makarov</surname><given-names>V</given-names></name><name><surname>Balachandran</surname><given-names>VP</given-names></name><name><surname>Hellmann</surname><given-names>MD</given-names></name><name><surname>Solovyov</surname><given-names>A</given-names></name><name><surname>Rizvi</surname><given-names>NA</given-names></name><name><surname>Merghoub</surname><given-names>T</given-names></name><name><surname>Levine</surname><given-names>AJ</given-names></name><name><surname>Chan</surname><given-names>TA</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Greenbaum</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy</article-title><source>Nature</source><volume>551</volume><fpage>517</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1038/nature24473</pub-id><pub-id pub-id-type="pmid">29132144</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mempel</surname><given-names>TR</given-names></name><name><surname>Bauer</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Intravital imaging of CD8+ T cell function in cancer</article-title><source>Clinical &amp; Experimental Metastasis</source><volume>26</volume><fpage>311</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1007/s10585-008-9196-9</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreira</surname><given-names>A</given-names></name><name><surname>Gross</surname><given-names>S</given-names></name><name><surname>Kirchberger</surname><given-names>MC</given-names></name><name><surname>Erdmann</surname><given-names>M</given-names></name><name><surname>Schuler</surname><given-names>G</given-names></name><name><surname>Heinzerling</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Senescence markers: Predictive for response to checkpoint inhibitors</article-title><source>Ternational Journal of Cancer</source><volume>144</volume><fpage>1147</fpage><lpage>1150</lpage><pub-id pub-id-type="doi">10.1002/ijc.31763</pub-id><pub-id pub-id-type="pmid">30151962</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>McDermott</surname><given-names>DF</given-names></name><name><surname>Redman</surname><given-names>BG</given-names></name><name><surname>Kuzel</surname><given-names>TM</given-names></name><name><surname>Harrison</surname><given-names>MR</given-names></name><name><surname>Vaishampayan</surname><given-names>UN</given-names></name><name><surname>Drabkin</surname><given-names>HA</given-names></name><name><surname>George</surname><given-names>S</given-names></name><name><surname>Logan</surname><given-names>TF</given-names></name><name><surname>Margolin</surname><given-names>KA</given-names></name><name><surname>Plimack</surname><given-names>ER</given-names></name><name><surname>Lambert</surname><given-names>AM</given-names></name><name><surname>Waxman</surname><given-names>IM</given-names></name><name><surname>Hammers</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial</article-title><source>Journal of Clinical Oncology</source><volume>33</volume><fpage>1430</fpage><lpage>1437</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.59.0703</pub-id><pub-id pub-id-type="pmid">25452452</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardoll</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The blockade of immune checkpoints in cancer immunotherapy</article-title><source>Nature Reviews. Cancer</source><volume>12</volume><fpage>252</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1038/nrc3239</pub-id><pub-id pub-id-type="pmid">22437870</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>YJ</given-names></name><name><surname>Kuen</surname><given-names>DS</given-names></name><name><surname>Chung</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance</article-title><source>Experimental &amp; Molecular Medicine</source><volume>50</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1038/s12276-018-0130-1</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pascal</surname><given-names>J</given-names></name><name><surname>Ashley</surname><given-names>CE</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Brocato</surname><given-names>TA</given-names></name><name><surname>Butner</surname><given-names>JD</given-names></name><name><surname>Carnes</surname><given-names>EC</given-names></name><name><surname>Koay</surname><given-names>EJ</given-names></name><name><surname>Brinker</surname><given-names>CJ</given-names></name><name><surname>Cristini</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2013">2013a</year><article-title>Mechanistic modeling identifies drug-uptake history as predictor of tumor drug resistance and nano-carrier-mediated response</article-title><source>ACS Nano</source><volume>7</volume><fpage>11174</fpage><lpage>11182</lpage><pub-id pub-id-type="doi">10.1021/nn4048974</pub-id><pub-id pub-id-type="pmid">24187963</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pascal</surname><given-names>J</given-names></name><name><surname>Bearer</surname><given-names>EL</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Koay</surname><given-names>EJ</given-names></name><name><surname>Curley</surname><given-names>SA</given-names></name><name><surname>Cristini</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2013">2013b</year><article-title>Mechanistic patient-specific predictive correlation of tumor drug response with microenvironment and perfusion measurements</article-title><source>PNAS</source><volume>110</volume><fpage>14266</fpage><lpage>14271</lpage><pub-id pub-id-type="doi">10.1073/pnas.1300619110</pub-id><pub-id pub-id-type="pmid">23940372</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pilard</surname><given-names>C</given-names></name><name><surname>Ancion</surname><given-names>M</given-names></name><name><surname>Delvenne</surname><given-names>P</given-names></name><name><surname>Jerusalem</surname><given-names>G</given-names></name><name><surname>Hubert</surname><given-names>P</given-names></name><name><surname>Herfs</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cancer immunotherapy: it’s time to better predict patients’ response</article-title><source>British Journal of Cancer</source><volume>125</volume><fpage>927</fpage><lpage>938</lpage><pub-id pub-id-type="doi">10.1038/s41416-021-01413-x</pub-id><pub-id pub-id-type="pmid">34112949</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Postow</surname><given-names>MA</given-names></name><name><surname>Callahan</surname><given-names>MK</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Immune checkpoint blockade in cancer therapy</article-title><source>Journal of Clinical Oncology</source><volume>33</volume><fpage>1974</fpage><lpage>1982</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.59.4358</pub-id><pub-id pub-id-type="pmid">25605845</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powles</surname><given-names>T</given-names></name><name><surname>Eder</surname><given-names>JP</given-names></name><name><surname>Fine</surname><given-names>GD</given-names></name><name><surname>Braiteh</surname><given-names>FS</given-names></name><name><surname>Loriot</surname><given-names>Y</given-names></name><name><surname>Cruz</surname><given-names>C</given-names></name><name><surname>Bellmunt</surname><given-names>J</given-names></name><name><surname>Burris</surname><given-names>HA</given-names></name><name><surname>Petrylak</surname><given-names>DP</given-names></name><name><surname>Teng</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Boyd</surname><given-names>Z</given-names></name><name><surname>Hegde</surname><given-names>PS</given-names></name><name><surname>Chen</surname><given-names>DS</given-names></name><name><surname>Vogelzang</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer</article-title><source>Nature</source><volume>515</volume><fpage>558</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1038/nature13904</pub-id><pub-id pub-id-type="pmid">25428503</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riaz</surname><given-names>N</given-names></name><name><surname>Havel</surname><given-names>JJ</given-names></name><name><surname>Makarov</surname><given-names>V</given-names></name><name><surname>Desrichard</surname><given-names>A</given-names></name><name><surname>Urba</surname><given-names>WJ</given-names></name><name><surname>Sims</surname><given-names>JS</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Martín-Algarra</surname><given-names>S</given-names></name><name><surname>Mandal</surname><given-names>R</given-names></name><name><surname>Sharfman</surname><given-names>WH</given-names></name><name><surname>Bhatia</surname><given-names>S</given-names></name><name><surname>Hwu</surname><given-names>W-J</given-names></name><name><surname>Gajewski</surname><given-names>TF</given-names></name><name><surname>Slingluff</surname><given-names>CL</given-names><suffix>Jr</suffix></name><name><surname>Chowell</surname><given-names>D</given-names></name><name><surname>Kendall</surname><given-names>SM</given-names></name><name><surname>Chang</surname><given-names>H</given-names></name><name><surname>Shah</surname><given-names>R</given-names></name><name><surname>Kuo</surname><given-names>F</given-names></name><name><surname>Morris</surname><given-names>LGT</given-names></name><name><surname>Sidhom</surname><given-names>J-W</given-names></name><name><surname>Schneck</surname><given-names>JP</given-names></name><name><surname>Horak</surname><given-names>CE</given-names></name><name><surname>Weinhold</surname><given-names>N</given-names></name><name><surname>Chan</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tumor and microenvironment evolution during immunotherapy with nivolumab</article-title><source>Cell</source><volume>171</volume><fpage>934</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.09.028</pub-id><pub-id pub-id-type="pmid">29033130</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Shin</surname><given-names>DS</given-names></name><name><surname>Zaretsky</surname><given-names>J</given-names></name><name><surname>Frederiksen</surname><given-names>J</given-names></name><name><surname>Cornish</surname><given-names>A</given-names></name><name><surname>Avramis</surname><given-names>E</given-names></name><name><surname>Seja</surname><given-names>E</given-names></name><name><surname>Kivork</surname><given-names>C</given-names></name><name><surname>Siebert</surname><given-names>J</given-names></name><name><surname>Kaplan-Lefko</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chmielowski</surname><given-names>B</given-names></name><name><surname>Glaspy</surname><given-names>JA</given-names></name><name><surname>Tumeh</surname><given-names>PC</given-names></name><name><surname>Chodon</surname><given-names>T</given-names></name><name><surname>Pe’er</surname><given-names>D</given-names></name><name><surname>Comin-Anduix</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>PD-1 blockade expands intratumoral memory T cells</article-title><source>Cancer Immunology Research</source><volume>4</volume><fpage>194</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-15-0210</pub-id><pub-id pub-id-type="pmid">26787823</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>Brady</surname><given-names>B</given-names></name><name><surname>Dutriaux</surname><given-names>C</given-names></name><name><surname>Maio</surname><given-names>M</given-names></name><name><surname>Mortier</surname><given-names>L</given-names></name><name><surname>Hassel</surname><given-names>JC</given-names></name><name><surname>Rutkowski</surname><given-names>P</given-names></name><name><surname>McNeil</surname><given-names>C</given-names></name><name><surname>Kalinka-Warzocha</surname><given-names>E</given-names></name><name><surname>Savage</surname><given-names>KJ</given-names></name><name><surname>Hernberg</surname><given-names>MM</given-names></name><name><surname>Lebbé</surname><given-names>C</given-names></name><name><surname>Charles</surname><given-names>J</given-names></name><name><surname>Mihalcioiu</surname><given-names>C</given-names></name><name><surname>Chiarion-Sileni</surname><given-names>V</given-names></name><name><surname>Mauch</surname><given-names>C</given-names></name><name><surname>Cognetti</surname><given-names>F</given-names></name><name><surname>Arance</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Gogas</surname><given-names>H</given-names></name><name><surname>Lundgren-Eriksson</surname><given-names>L</given-names></name><name><surname>Horak</surname><given-names>C</given-names></name><name><surname>Sharkey</surname><given-names>B</given-names></name><name><surname>Waxman</surname><given-names>IM</given-names></name><name><surname>Atkinson</surname><given-names>V</given-names></name><name><surname>Ascierto</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2015">2015a</year><article-title>Nivolumab in previously untreated melanoma without BRAF mutation</article-title><source>The New England Journal of Medicine</source><volume>372</volume><fpage>320</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1412082</pub-id><pub-id pub-id-type="pmid">25399552</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Schachter</surname><given-names>J</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>Arance</surname><given-names>A</given-names></name><name><surname>Grob</surname><given-names>JJ</given-names></name><name><surname>Mortier</surname><given-names>L</given-names></name><name><surname>Daud</surname><given-names>A</given-names></name><name><surname>Carlino</surname><given-names>MS</given-names></name><name><surname>McNeil</surname><given-names>C</given-names></name><name><surname>Lotem</surname><given-names>M</given-names></name><name><surname>Larkin</surname><given-names>J</given-names></name><name><surname>Lorigan</surname><given-names>P</given-names></name><name><surname>Neyns</surname><given-names>B</given-names></name><name><surname>Blank</surname><given-names>CU</given-names></name><name><surname>Hamid</surname><given-names>O</given-names></name><name><surname>Mateus</surname><given-names>C</given-names></name><name><surname>Shapira-Frommer</surname><given-names>R</given-names></name><name><surname>Kosh</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Ibrahim</surname><given-names>N</given-names></name><name><surname>Ebbinghaus</surname><given-names>S</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><collab>KEYNOTE-006 investigators</collab></person-group><year iso-8601-date="2015">2015b</year><article-title>Pembrolizumab versus ipilimumab in advanced melanoma</article-title><source>The New England Journal of Medicine</source><volume>372</volume><fpage>2521</fpage><lpage>2532</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1503093</pub-id><pub-id pub-id-type="pmid">25891173</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Rohatgi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>WebPlotDigitalizer: HTML5 based online tool to extractnumerical data from plot images</article-title><ext-link ext-link-type="uri" xlink:href="https://automeris.io/WebPlotDigitizer">https://automeris.io/WebPlotDigitizer</ext-link><date-in-citation iso-8601-date="2019-04-11">April 11, 2019</date-in-citation></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serre</surname><given-names>R</given-names></name><name><surname>Benzekry</surname><given-names>S</given-names></name><name><surname>Padovani</surname><given-names>L</given-names></name><name><surname>Meille</surname><given-names>C</given-names></name><name><surname>André</surname><given-names>N</given-names></name><name><surname>Ciccolini</surname><given-names>J</given-names></name><name><surname>Barlesi</surname><given-names>F</given-names></name><name><surname>Muracciole</surname><given-names>X</given-names></name><name><surname>Barbolosi</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mathematical modeling of cancer immunotherapy and its synergy with radiotherapy</article-title><source>Cancer Research</source><volume>76</volume><fpage>4931</fpage><lpage>4940</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-3567</pub-id><pub-id pub-id-type="pmid">27302167</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Hu-Lieskovan</surname><given-names>S</given-names></name><name><surname>Wargo</surname><given-names>JA</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Primary, adaptive, and acquired resistance to cancer immunotherapy</article-title><source>Cell</source><volume>168</volume><fpage>707</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.01.017</pub-id><pub-id pub-id-type="pmid">28187290</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spira</surname><given-names>AI</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Mazières</surname><given-names>J</given-names></name><name><surname>Vansteenkiste</surname><given-names>JF</given-names></name><name><surname>Rittmeyer</surname><given-names>A</given-names></name><name><surname>Ballinger</surname><given-names>M</given-names></name><name><surname>Waterkamp</surname><given-names>D</given-names></name><name><surname>Kowanetz</surname><given-names>M</given-names></name><name><surname>Mokatrin</surname><given-names>A</given-names></name><name><surname>Fehrenbacher</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR)</article-title><source>Journal of Clinical Oncology</source><volume>33</volume><elocation-id>8010</elocation-id><pub-id pub-id-type="doi">10.1200/jco.2015.33.15_suppl.8010</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>WD</given-names></name><name><surname>Figg</surname><given-names>WD</given-names></name><name><surname>Dahut</surname><given-names>W</given-names></name><name><surname>Stein</surname><given-names>AD</given-names></name><name><surname>Hoshen</surname><given-names>MB</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Bates</surname><given-names>SE</given-names></name><name><surname>Fojo</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data</article-title><source>The Oncologist</source><volume>13</volume><fpage>1046</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2008-0075</pub-id><pub-id pub-id-type="pmid">18838440</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taube</surname><given-names>JM</given-names></name><name><surname>Klein</surname><given-names>A</given-names></name><name><surname>Brahmer</surname><given-names>JR</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Pardoll</surname><given-names>DM</given-names></name><name><surname>Topalian</surname><given-names>SL</given-names></name><name><surname>Anders</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy</article-title><source>Clinical Cancer Research</source><volume>20</volume><fpage>5064</fpage><lpage>5074</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-3271</pub-id><pub-id pub-id-type="pmid">24714771</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname><given-names>MWL</given-names></name><name><surname>Ngiow</surname><given-names>SF</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Classifying cancers based on T-cell infiltration and PD-L1</article-title><source>Cancer Research</source><volume>75</volume><fpage>2139</fpage><lpage>2145</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-0255</pub-id><pub-id pub-id-type="pmid">25977340</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topalian</surname><given-names>SL</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Brahmer</surname><given-names>JR</given-names></name><name><surname>Gettinger</surname><given-names>SN</given-names></name><name><surname>Smith</surname><given-names>DC</given-names></name><name><surname>McDermott</surname><given-names>DF</given-names></name><name><surname>Powderly</surname><given-names>JD</given-names></name><name><surname>Carvajal</surname><given-names>RD</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Atkins</surname><given-names>MB</given-names></name><name><surname>Leming</surname><given-names>PD</given-names></name><name><surname>Spigel</surname><given-names>DR</given-names></name><name><surname>Antonia</surname><given-names>SJ</given-names></name><name><surname>Horn</surname><given-names>L</given-names></name><name><surname>Drake</surname><given-names>CG</given-names></name><name><surname>Pardoll</surname><given-names>DM</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Sharfman</surname><given-names>WH</given-names></name><name><surname>Anders</surname><given-names>RA</given-names></name><name><surname>Taube</surname><given-names>JM</given-names></name><name><surname>McMiller</surname><given-names>TL</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Korman</surname><given-names>AJ</given-names></name><name><surname>Jure-Kunkel</surname><given-names>M</given-names></name><name><surname>Agrawal</surname><given-names>S</given-names></name><name><surname>McDonald</surname><given-names>D</given-names></name><name><surname>Kollia</surname><given-names>GD</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Wigginton</surname><given-names>JM</given-names></name><name><surname>Sznol</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Safety, activity, and immune correlates of anti-PD-1 antibody in cancer</article-title><source>The New England Journal of Medicine</source><volume>366</volume><fpage>2443</fpage><lpage>2454</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1200690</pub-id><pub-id pub-id-type="pmid">22658127</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tumeh</surname><given-names>PC</given-names></name><name><surname>Harview</surname><given-names>CL</given-names></name><name><surname>Yearley</surname><given-names>JH</given-names></name><name><surname>Shintaku</surname><given-names>IP</given-names></name><name><surname>Taylor</surname><given-names>EJM</given-names></name><name><surname>Robert</surname><given-names>L</given-names></name><name><surname>Chmielowski</surname><given-names>B</given-names></name><name><surname>Spasic</surname><given-names>M</given-names></name><name><surname>Henry</surname><given-names>G</given-names></name><name><surname>Ciobanu</surname><given-names>V</given-names></name><name><surname>West</surname><given-names>AN</given-names></name><name><surname>Carmona</surname><given-names>M</given-names></name><name><surname>Kivork</surname><given-names>C</given-names></name><name><surname>Seja</surname><given-names>E</given-names></name><name><surname>Cherry</surname><given-names>G</given-names></name><name><surname>Gutierrez</surname><given-names>AJ</given-names></name><name><surname>Grogan</surname><given-names>TR</given-names></name><name><surname>Mateus</surname><given-names>C</given-names></name><name><surname>Tomasic</surname><given-names>G</given-names></name><name><surname>Glaspy</surname><given-names>JA</given-names></name><name><surname>Emerson</surname><given-names>RO</given-names></name><name><surname>Robins</surname><given-names>H</given-names></name><name><surname>Pierce</surname><given-names>RH</given-names></name><name><surname>Elashoff</surname><given-names>DA</given-names></name><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>PD-1 blockade induces responses by inhibiting adaptive immune resistance</article-title><source>Nature</source><volume>515</volume><fpage>568</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1038/nature13954</pub-id><pub-id pub-id-type="pmid">25428505</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallejo</surname><given-names>AN</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>CD28 extinction in human T cells: altered functions and the program of T-cell senescence</article-title><source>Immunological Reviews</source><volume>205</volume><fpage>158</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1111/j.0105-2896.2005.00256.x</pub-id><pub-id pub-id-type="pmid">15882352</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Butner</surname><given-names>JD</given-names></name><name><surname>Kerketta</surname><given-names>R</given-names></name><name><surname>Cristini</surname><given-names>V</given-names></name><name><surname>Deisboeck</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Simulating cancer growth with multiscale agent-based modeling</article-title><source>Seminars in Cancer Biology</source><volume>30</volume><fpage>70</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2014.04.001</pub-id><pub-id pub-id-type="pmid">24793698</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Kerketta</surname><given-names>R</given-names></name><name><surname>Chuang</surname><given-names>Y-L</given-names></name><name><surname>Dogra</surname><given-names>P</given-names></name><name><surname>Butner</surname><given-names>JD</given-names></name><name><surname>Brocato</surname><given-names>TA</given-names></name><name><surname>Day</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Simbawa</surname><given-names>E</given-names></name><name><surname>AL-Fhaid</surname><given-names>AS</given-names></name><name><surname>Mahmoud</surname><given-names>SR</given-names></name><name><surname>Curley</surname><given-names>SA</given-names></name><name><surname>Ferrari</surname><given-names>M</given-names></name><name><surname>Koay</surname><given-names>EJ</given-names></name><name><surname>Cristini</surname><given-names>V</given-names></name><name><surname>Di Bernardo</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Theory and experimental validation of a spatio-temporal model of chemotherapy transport to enhance tumor cell kill</article-title><source>PLOS Computational Biology</source><volume>12</volume><elocation-id>e1004969</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1004969</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>JS</given-names></name><name><surname>D’Angelo</surname><given-names>SP</given-names></name><name><surname>Minor</surname><given-names>D</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Gutzmer</surname><given-names>R</given-names></name><name><surname>Neyns</surname><given-names>B</given-names></name><name><surname>Hoeller</surname><given-names>C</given-names></name><name><surname>Khushalani</surname><given-names>NI</given-names></name><name><surname>Miller</surname><given-names>WH</given-names><suffix>Jr</suffix></name><name><surname>Lao</surname><given-names>CD</given-names></name><name><surname>Linette</surname><given-names>GP</given-names></name><name><surname>Thomas</surname><given-names>L</given-names></name><name><surname>Lorigan</surname><given-names>P</given-names></name><name><surname>Grossmann</surname><given-names>KF</given-names></name><name><surname>Hassel</surname><given-names>JC</given-names></name><name><surname>Maio</surname><given-names>M</given-names></name><name><surname>Sznol</surname><given-names>M</given-names></name><name><surname>Ascierto</surname><given-names>PA</given-names></name><name><surname>Mohr</surname><given-names>P</given-names></name><name><surname>Chmielowski</surname><given-names>B</given-names></name><name><surname>Bryce</surname><given-names>A</given-names></name><name><surname>Svane</surname><given-names>IM</given-names></name><name><surname>Grob</surname><given-names>J-J</given-names></name><name><surname>Krackhardt</surname><given-names>AM</given-names></name><name><surname>Horak</surname><given-names>C</given-names></name><name><surname>Lambert</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>AS</given-names></name><name><surname>Larkin</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial</article-title><source>The Lancet. Oncology</source><volume>16</volume><fpage>375</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(15)70076-8</pub-id><pub-id pub-id-type="pmid">25795410</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkie</surname><given-names>KP</given-names></name><name><surname>Hahnfeldt</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Tumor-immune dynamics regulated in the microenvironment inform the transient nature of immune-induced tumor dormancy</article-title><source>Cancer Research</source><volume>73</volume><fpage>3534</fpage><lpage>3544</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-4590</pub-id><pub-id pub-id-type="pmid">23536560</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="software"><person-group person-group-type="author"><collab>Wolfram Research I</collab></person-group><year iso-8601-date="2017">2017</year><data-title>Illinois</data-title><version designator="11.2">11.2</version><source>MathematicaChampaign</source><ext-link ext-link-type="uri" xlink:href="https://www.wolfram.com/mathematica/">https://www.wolfram.com/mathematica/</ext-link></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec id="s8" sec-type="appendix"><title>Immunotherapy model derivation</title><p>The mechanistic model of cancer immunotherapy presented in this paper is essentially an extension of our prior mathematical model describing chemotherapy response that has been shown to predict cancer cell kill with various cytotoxic or targeted agents. In particular, we extend these equations to consider immune cell presence as necessary for cancer cell kill secondary to immunotherapy, and that immune cells respond to not only diffusion gradients within a tumor microenvironment but can also be influenced by the presence of cytokines through cell signaling pathways and chemotaxis. The model hypothesis of immunotherapy presented here is that these molecules or antibodies diffuse and block the complimentary interaction between immune checkpoint ligands expressed on cancer cells with their complementary proteins on immune cells. This mechanism renders effector immune cells potentially active for cancer cell killing; thus, the therapeutic site of action occurs within the tumor microenvironment (i.e., because our model only describes the tumor region and the factors and processes contained therein, we have made the assumption that all key mechanisms such as drug binding occur only within the tumor). These assumptions lead to the following system of PDEs:<disp-formula id="equ3"><label>(A1)</label><mml:math id="m3"><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">∂</mml:mi><mml:mi>ρ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">∂</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>α</mml:mi><mml:mo>⋅</mml:mo><mml:mi>ρ</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mtext>p</mml:mtext></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi>ρ</mml:mi><mml:mo>⋅</mml:mo><mml:msub><mml:mi>ψ</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:msubsup><mml:mo>∫</mml:mo><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msubsup><mml:mi>λ</mml:mi><mml:mo>⋅</mml:mo><mml:mi>σ</mml:mi><mml:mo>⋅</mml:mo><mml:mi>ρ</mml:mi><mml:mo>⋅</mml:mo><mml:mtext>d</mml:mtext><mml:msup><mml:mi>t</mml:mi><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></disp-formula><disp-formula id="equ4"><label>(A2)</label><mml:math id="m4"><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">∂</mml:mi><mml:msub><mml:mi>ψ</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">∂</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mi>χ</mml:mi><mml:mo>⋅</mml:mo><mml:mi mathvariant="normal">∇</mml:mi><mml:mo>⋅</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>ψ</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi mathvariant="normal">∇</mml:mi><mml:mo>⋅</mml:mo><mml:mi>C</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">Λ</mml:mi><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">∂</mml:mi><mml:mi>ρ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">∂</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mi>α</mml:mi><mml:mo>⋅</mml:mo><mml:mi>ρ</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="equ5"><label>(A3)</label><mml:math id="m5"><mml:mrow><mml:mn>0</mml:mn><mml:mo>=</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>⋅</mml:mo><mml:msup><mml:mi mathvariant="normal">∇</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mi>σ</mml:mi><mml:mo>−</mml:mo><mml:mi>λ</mml:mi><mml:mo>⋅</mml:mo><mml:mi>σ</mml:mi><mml:mo>⋅</mml:mo><mml:mi>ρ</mml:mi></mml:mrow></mml:math></disp-formula><disp-formula id="equ6"><label>(A4)</label><mml:math id="m6"><mml:mrow><mml:mn>0</mml:mn><mml:mo>=</mml:mo><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:msup><mml:mi mathvariant="normal">∇</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mi>C</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">Λ</mml:mi><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi>λ</mml:mi><mml:mo>⋅</mml:mo><mml:mi>σ</mml:mi><mml:mo>⋅</mml:mo><mml:mi>ρ</mml:mi></mml:mrow></mml:math></disp-formula></p><p>Here <inline-formula><mml:math id="inf19"><mml:mi>ρ</mml:mi></mml:math></inline-formula>, <inline-formula><mml:math id="inf20"><mml:msub><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> , <inline-formula><mml:math id="inf21"><mml:mi>σ</mml:mi></mml:math></inline-formula>, and <inline-formula><mml:math id="inf22"><mml:mi>C</mml:mi></mml:math></inline-formula> represent the local concentration of cancer cells, therapeutic immune cells, immunotherapy antibodies, and cytokines, respectively. Moreover, <italic>α</italic> is the proliferation rate of tumor cells, <inline-formula><mml:math id="inf23"><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is the specific death rate of cancer cells, <inline-formula><mml:math id="inf24"><mml:mi>λ</mml:mi></mml:math></inline-formula> is the binding coefficient of immunotherapy antibodies that block the interaction between immune inhibitory ligands on cancer cells and their counterparts on immune cells, <inline-formula><mml:math id="inf25"><mml:msub><mml:mrow><mml:mi>Λ</mml:mi></mml:mrow><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is the coupling of immune cell activity relative to the number of cancer cells (i.e., killing and tumor infiltration capacity of the host immune system), <italic>χ</italic> is the chemotaxis coefficient, <italic>Λ<sub>C</sub></italic> is the number of released cytokines as immunotherapy antibodies are bound, and <italic>D<sub>a</sub></italic> and <italic>D<sub>c</sub></italic> are the diffusivity of antibodies and cytokines (see also <xref ref-type="fig" rid="fig1">Figure 1</xref>, main text).</p><p>The first equation describes the death rate of cancer cells as proportional to the concentration of therapeutic immune cells and the time history of immunotherapy antibody uptake and binding within the tumor environment. The second equation represents mass conservation of ‘effective’ therapeutic immune cells, including the rate at which these cells become ineffective at killing cancer cells. The third and fourth equations represent the concentration and diffusion of immunotherapy antibodies and cytokines in the presence of immunotherapy antibody binding.</p><p>To compare this mechanistic model with clinical immunotherapy data, we make multiple reductionist assumptions about the influence of various parameters from <xref ref-type="disp-formula" rid="equ1">Equation A1-4</xref> on immunotherapy response. These assumptions suppose that immune cells are in relatively close physical proximity to cancer cells, allowing one to ignore the influence of cytokines to guide their movement, and that the primary effector immune cell response to immunotherapy is driven by the presence of immune cells already present in the tumor at the initiation of the therapy. Furthermore, we assume uptake and binding of immunotherapy antibodies within the tumor environment to occur diffusely relative to cancer and immune cell concentrations; therefore, in this model, we set <inline-formula><mml:math id="inf26"><mml:mi>χ</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula> and remove the influence of immunotherapy antibody concentration. These assumptions reduced the four PDEs to the following set of coupled ODEs as follows:<disp-formula id="equ7"><label>(A5)</label><mml:math id="m7"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>ρ</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>α</mml:mi><mml:mo>⋅</mml:mo><mml:mi>ρ</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mtext>p</mml:mtext></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi>ρ</mml:mi><mml:mo>⋅</mml:mo><mml:msub><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow><mml:msubsup><mml:mo>∫</mml:mo><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mi>λ</mml:mi><mml:mo>⋅</mml:mo><mml:mi>σ</mml:mi><mml:mo>⋅</mml:mo><mml:mi>ρ</mml:mi></mml:mrow></mml:mrow><mml:mo>⋅</mml:mo><mml:mtext>d</mml:mtext><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:math></disp-formula><disp-formula id="equ8"><label>(A6)</label><mml:math id="m8"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>Λ</mml:mi></mml:mrow><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>ρ</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>-</mml:mo><mml:mi>α</mml:mi><mml:mo>⋅</mml:mo><mml:mi>ρ</mml:mi></mml:mrow></mml:mfenced></mml:math></disp-formula></p><p>Here, <xref ref-type="disp-formula" rid="equ8">Equation A6</xref> represents the change in tumor-infiltrating immune cells relative to the change in cancer cells killed by the immune system. In the case where immune cell killing is weak (i.e., <inline-formula><mml:math id="inf27"><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>≅</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>, and thus <inline-formula><mml:math id="inf28"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>ρ</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>α</mml:mi><mml:mo>⋅</mml:mo><mml:mi>ρ</mml:mi></mml:math></inline-formula>), the change in immune cell concentration within the tumor is negligible compared to the growth of the tumor, thus <xref ref-type="disp-formula" rid="equ8">Equation A6</xref> satisfies the relationship <inline-formula><mml:math id="inf29"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>≅</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula> (i.e., immune cell concentration within the tumor remains roughly constant over time). When immune cell killing is sufficiently effective, then</p><p><inline-formula><mml:math id="inf30"><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mtext>p</mml:mtext></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi>ρ</mml:mi><mml:mo>⋅</mml:mo><mml:msub><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow><mml:msubsup><mml:mo>∫</mml:mo><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mi>λ</mml:mi><mml:mo>⋅</mml:mo><mml:mi>σ</mml:mi><mml:mo>⋅</mml:mo><mml:mi>ρ</mml:mi></mml:mrow></mml:mrow><mml:mo>⋅</mml:mo><mml:mtext>d</mml:mtext><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>§amp;gt;</mml:mo><mml:mi>α</mml:mi><mml:mo>⋅</mml:mo><mml:mi>ρ</mml:mi></mml:math></inline-formula> and thus <inline-formula><mml:math id="inf31"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>≅</mml:mo><mml:msub><mml:mrow><mml:mi>Λ</mml:mi></mml:mrow><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>ρ</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:math></inline-formula> . In essence, the change in immune cells in the tumor over time is roughly equal to the immune cell coupling to cancer cells [i.e., immune cells in the tumor environment are related to the tumor volume by a coupling factor (<inline-formula><mml:math id="inf32"><mml:msub><mml:mrow><mml:mi>Λ</mml:mi></mml:mrow><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>)], which captures the immunogenicity of an individual tumor. Integrating both sides of <xref ref-type="disp-formula" rid="equ8">Equation A6</xref> over time leads to the following relationship:<disp-formula id="equ9"><label>(A7)</label><mml:math id="m9"><mml:msub><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>Λ</mml:mi></mml:mrow><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>ρ</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>ρ</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf33"><mml:msub><mml:mrow><mml:mi>ρ</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="inf34"><mml:msub><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> represent the concentration of tumor cells and immune cells at the start of immunotherapy. We then substitute <inline-formula><mml:math id="inf35"><mml:msub><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> from, <xref ref-type="disp-formula" rid="equ1">Equation (A7) into Equation (A5)</xref> express <inline-formula><mml:math id="inf36"><mml:msub><mml:mrow><mml:mi>Λ</mml:mi></mml:mrow><mml:mrow><mml:mi>ψ</mml:mi><mml:mi>ρ</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:msub><mml:mrow><mml:mi>Λ</mml:mi></mml:mrow><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi>ρ</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>ψ</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> , and replace the concentration of tumor cells <inline-formula><mml:math id="inf37"><mml:mi>ρ</mml:mi></mml:math></inline-formula> by a proportion of the original tumor cell concentration to obtain the normalized tumor mass <inline-formula><mml:math id="inf38"><mml:msup><mml:mrow><mml:mi>ρ</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mi>ρ</mml:mi></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>ρ</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> (while noting that one may also use normalized tumor volume here) to give us one equation of tumor response represented by<disp-formula id="equ10"><label>(A8)</label><mml:math id="m10"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mi>ρ</mml:mi><mml:mi>`</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>α</mml:mi><mml:mo>⋅</mml:mo><mml:mi>ρ</mml:mi><mml:mi>`</mml:mi><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mtext>p</mml:mtext></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi>ρ</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>⋅</mml:mo><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>Λ</mml:mi></mml:mrow><mml:mrow><mml:mi>ψ</mml:mi><mml:mi>ρ</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:msup><mml:mrow><mml:mi>ρ</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mfenced><mml:mo>⋅</mml:mo><mml:mrow><mml:msubsup><mml:mo>∫</mml:mo><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mi>λ</mml:mi><mml:mo>⋅</mml:mo><mml:mi>σ</mml:mi><mml:mo>⋅</mml:mo><mml:mi>ρ</mml:mi><mml:mi>`</mml:mi></mml:mrow></mml:mrow><mml:mo>⋅</mml:mo><mml:mtext>d</mml:mtext><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:math></disp-formula></p><p>Finally, we assume that the binding of immunotherapy antibodies within the tumor environment (<inline-formula><mml:math id="inf39"><mml:mrow><mml:msubsup><mml:mo>∫</mml:mo><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:mi>λ</mml:mi><mml:mo>⋅</mml:mo><mml:mi>σ</mml:mi><mml:mo>⋅</mml:mo><mml:mi>ρ</mml:mi><mml:mi>`</mml:mi></mml:mrow></mml:mrow><mml:mo>⋅</mml:mo><mml:mtext>d</mml:mtext><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>`</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula>) and rate of tumor cell death secondary to effector immune cells (<inline-formula><mml:math id="inf40"><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mtext>p</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula>) reach constant steady states on time scales faster than measurable tumor cell kill, implying <inline-formula><mml:math id="inf41"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mtext>p</mml:mtext></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:msubsup><mml:mo>∫</mml:mo><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msubsup><mml:mi>λ</mml:mi><mml:mo>⋅</mml:mo><mml:mi>σ</mml:mi><mml:mo>⋅</mml:mo><mml:msup><mml:mi>ρ</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo>⋅</mml:mo><mml:mtext>d</mml:mtext><mml:msup><mml:mi>t</mml:mi><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mi>μ</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>, leading to<disp-formula id="equ11"><label>(A9)</label><mml:math id="m11"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msup><mml:mi>ρ</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow><mml:mrow><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>α</mml:mi><mml:mo>⋅</mml:mo><mml:msup><mml:mi>ρ</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo>−</mml:mo><mml:msup><mml:mi>ρ</mml:mi><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msup><mml:mo>⋅</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">Λ</mml:mi><mml:mrow><mml:mi>ψ</mml:mi><mml:mi>ρ</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mi>ρ</mml:mi><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>⋅</mml:mo><mml:mi>μ</mml:mi></mml:mrow></mml:math></disp-formula></p><p>This ODE can be solved analytically for <inline-formula><mml:math id="inf42"><mml:mi>ρ</mml:mi><mml:mi>`</mml:mi></mml:math></inline-formula> by integrating both sides, yielding<disp-formula id="equ12"><label>(A10)</label><mml:math id="m12"><mml:mrow><mml:msup><mml:mi>ρ</mml:mi><mml:mrow><mml:mo>′</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi>α</mml:mi><mml:mo>−</mml:mo><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi>μ</mml:mi><mml:mo>⋅</mml:mo><mml:msub><mml:mi mathvariant="normal">Λ</mml:mi><mml:mrow><mml:mi>ψ</mml:mi><mml:mi>ρ</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:mi>α</mml:mi><mml:mo>−</mml:mo><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi>μ</mml:mi><mml:mo>⋅</mml:mo><mml:msub><mml:mi mathvariant="normal">Λ</mml:mi><mml:mrow><mml:mi>ψ</mml:mi><mml:mi>ρ</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>α</mml:mi><mml:mo>−</mml:mo><mml:mi>μ</mml:mi><mml:mo>+</mml:mo><mml:mi>μ</mml:mi><mml:mo>⋅</mml:mo><mml:msub><mml:mi mathvariant="normal">Λ</mml:mi><mml:mrow><mml:mi>ψ</mml:mi><mml:mi>ρ</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>⋅</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p><xref ref-type="disp-formula" rid="equ12">Equation A10</xref> is the same as <xref ref-type="disp-formula" rid="equ1">Equation (1)</xref> in the primary text, which is used to compare with clinical response data to immunotherapy.</p><fig id="app1fig1" position="float"><label>Appendix 1—figure 1.</label><caption><title>Steps for calibration of the mathematical model with clinical data.</title><p>First, checkpoint inhibitor response curves were extracted from the literature. In all cases, immunotherapy treatment began at time <italic>t</italic> = 0. Second, a tumor-specific proliferation constant (<italic>α</italic>) was determined for each cancer type by fitting exponential function (<inline-formula><mml:math id="inf43"><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>α</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula> to fastest progressing patient in each clinical trial [red line]). Third, individual patient response data were fit to <xref ref-type="disp-formula" rid="equ1">Equation (1)</xref> by using the respective α to determine <italic>Λ</italic> and <italic>µ. Λ</italic> and <italic>µ</italic> values were then with compared in patients with partial/complete response versus patients with stable/progressive disease after immunotherapy by using the RECIST v1.1 criteria.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70130-app1-fig1-v2.tif"/></fig><fig id="app1fig2" position="float"><label>Appendix 1—figure 2.</label><caption><title>Model validation, sensitivity studies, and comparison of model parameters to immunohistochemical (IHC) measures.</title><p>Model parameters were obtained from a second in-house patient cohort of patients with non-small cell lung cancer (NSCLC) (n = 64), which were compared to values obtained in the calibration cohort in a validation study. To study the sensitivity of the model to changes in model parameter values, key parameters were perturbed ±10% and the resultant simulated expected tumor burden was compared to measured values pre-perturbation. Tumor burden measures were also truncated, and results of truncated and full dataset model fits were compared. Lastly, the full parameter space of the model was examined. In order to compare model parameters to the underlying biology, model parameters were converted to intratumoral CD8+ lymphocyte counts (for <italic>Λ</italic>) and PD-L1 staining (for <italic>μ</italic>), which were compared to IHC measures obtained from the literature.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70130-app1-fig2-v2.tif"/></fig><fig id="app1fig3" position="float"><label>Appendix 1—figure 3.</label><caption><title>Parameter validation analysis within the calibration cohort.</title><p>In order to examine the robustness of ranges for (<bold>A</bold>) parameter <italic>Λ</italic> and (<bold>B</bold>) parameter <italic>μ</italic> between partial and complete response (PR/CR) versus stable/progressive disease among different cancer types, a validation study was performed where one cancer type was removed from the calibration cohort and used as validation against the parameter ranges in the reduced calibration set obtained from <xref ref-type="bibr" rid="bib4">Borghaei et al., 2015</xref>; <xref ref-type="bibr" rid="bib2">Antonia et al., 2015</xref>; <xref ref-type="bibr" rid="bib39">Le et al., 2015</xref>; <xref ref-type="bibr" rid="bib44">Motzer et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">Powles et al., 2014</xref>; and <xref ref-type="bibr" rid="bib63">Topalian et al., 2012</xref>. Analysis was repeated once for each cancer type, and results are shown as mean ± standard deviation (error bars). Parameter ranges were found to vary between individual cancer types, and with <italic>μ</italic> showing more consistent significant difference between response categories relative to <italic>Λ</italic> (these results are consistent with results shown in <xref ref-type="bibr" rid="bib10">Butner et al., 2020</xref>).</p><p><supplementary-material id="app1fig3sdata1"><label>Appendix 1—figure 3—source data 1.</label><caption><title>Numerical data for <xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-70130-app1-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-70130-app1-fig3-v2.tif"/></fig><table-wrap id="app1table1" position="float"><label>Appendix 1—table 1.</label><caption><title>Studies used for derivation of pathological markers of immunotherapy response.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Reference (see main text)</th><th align="left" valign="top">Tumor type</th><th align="left" valign="top">Checkpoint inhibitor</th><th align="left" valign="top">Pathological biomarker</th><th align="left" valign="top">PD-L1 staining cutoff</th></tr></thead><tbody><tr><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib64">Tumeh et al., 2014</xref></td><td align="left" valign="top">Melanoma</td><td align="left" valign="top">Pembrolizumab</td><td align="left" valign="top">CD8+ TILs</td><td align="left" valign="top">N/A</td></tr><tr><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib36">Kefford et al., 2014</xref></td><td align="left" valign="top">Melanoma</td><td align="left" valign="top">Pembrolizumab</td><td align="left" valign="top">PD-L1</td><td align="char" char="." valign="top">1%</td></tr><tr><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib51">Powles et al., 2014</xref></td><td align="left" valign="top">UCC</td><td align="left" valign="top">Atezolizumab</td><td align="left" valign="top">PD-L1</td><td align="char" char="." valign="top">1%, 5%, 10%</td></tr><tr><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib31">Herbst et al., 2014</xref></td><td align="left" valign="top">NSCLC, RCC, melanoma, HNSCC, CRC, gastric and pancreatic cancer</td><td align="left" valign="top">Atezolizumab</td><td align="left" valign="top">PD-L1</td><td align="char" char="." valign="top">1%, 5%, 10%</td></tr><tr><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib55">Robert et al., 2015b</xref></td><td align="left" valign="top">Melanoma</td><td align="left" valign="top">Nivolumab</td><td align="left" valign="top">PD-L1</td><td align="char" char="." valign="top">5%</td></tr><tr><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib44">Motzer et al., 2015</xref></td><td align="left" valign="top">RCC</td><td align="left" valign="top">Nivolumab</td><td align="left" valign="top">PD-L1</td><td align="char" char="." valign="top">5%</td></tr><tr><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib61">Taube et al., 2014</xref></td><td align="left" valign="top">NSCLC, RCC, melanoma, PC, CRC</td><td align="left" valign="top">Nivolumab</td><td align="left" valign="top">PD-L1</td><td align="char" char="." valign="top">5%</td></tr><tr><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib59">Spira et al., 2015</xref></td><td align="left" valign="top">NSCLC</td><td align="left" valign="top">Atezolizumab</td><td align="left" valign="top">PD-L1</td><td align="char" char="." valign="top">1%, 5%, 10%</td></tr><tr><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib5">Brahmer et al., 2012</xref></td><td align="left" valign="top">NSCLC</td><td align="left" valign="top">Nivolumab</td><td align="left" valign="top">PD-L1</td><td align="char" char="." valign="top">1%, 5%, 10%</td></tr><tr><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib4">Borghaei et al., 2015</xref></td><td align="left" valign="top">NSCLC</td><td align="left" valign="top">Nivolumab</td><td align="left" valign="top">PD-L1</td><td align="char" char="." valign="top">1%, 5%, 10%</td></tr><tr><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib68">Weber et al., 2015</xref></td><td align="left" valign="top">Melanoma</td><td align="left" valign="top">Nivolumab</td><td align="left" valign="top">PD-L1</td><td align="char" char="." valign="top">5%</td></tr><tr><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib63">Topalian et al., 2012</xref></td><td align="left" valign="top">Melanoma, RCC, NSCLC, CRC, PC</td><td align="left" valign="top">Nivolumab</td><td align="left" valign="top">PD-L1</td><td align="char" char="." valign="top">5%</td></tr><tr><td align="char" char="." valign="top"><xref ref-type="bibr" rid="bib25">Garon et al., 2015</xref></td><td align="left" valign="top">NSCLC</td><td align="left" valign="top">Pembrolizumab</td><td align="left" valign="top">PD-L1</td><td align="char" char="." valign="top">1%, 50%</td></tr></tbody></table><table-wrap-foot><fn><p>RCC: renal cell; UCC: urothelial cell carcinoma; CRC: colorectal carcinoma; NSCLC: non-small lung carcinoma; HNSCC: head and neck squamous cell carcinoma; PC: prostate carcinoma; TIL: tumor-infiltrating lymphocytes</p></fn></table-wrap-foot></table-wrap></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.70130.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Caigang</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Shengjing Hospital of China Medical University</institution><country>China</country></aff></contrib></contrib-group></front-stub><body><p>A mathematical model was established for predicting immunotherapy efficacy in this work. With three convenient available clinical parameters, the model has exhibited considerable predictive capacity with stable performance across several tumor types. It may show great promise in selecting participants for prospective trials and guiding targeted application of immunotherapy in cancer patients.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.70130.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Liu</surname><given-names>Caigang</given-names></name><role>Reviewing Editor</role><aff><institution>Shengjing Hospital of China Medical University</institution><country>China</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.05.10.21256419">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2021.05.10.21256419v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Mone Zaidi as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Multiple parameters could reflect treatment efficacy of immunotherapy to cancers while three specific parameters were included in this model, the selection process and reasons for choosing these three parameters need to be described in detail, the definition of the three parameters seems to in discordant with clinical setting which requires further explanation.</p><p>2) As a heterogenous entity, different types of cancer possess distinct features, rationality to employ this model as one fit-in-all with a relatively small training cohort requires additional discussion after validated in a large-scale validation cohort.</p><p>3) As a novel model evaluation of the sensitivity and accuracy needs to be addressed, and comparison of this model with current applied parameters for predicting immunotherapy treatment efficacy requires to be supplemented.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The authors demonstrate a translational mathematical model dependent on three key parameters for describing efficacy of checkpoint inhibitors in human cancer. This paper describes some very interesting work. However, it remains questions that need to be addressed as follows:</p><p>1. The authors need present why they select these three parameters for describing efficacy of checkpoint inhibitors in human cancer. How about other factors?</p><p>2. How can the authors make sure that this model is suitable for all human cancer? Is the clinical tumor response dataset (n = 189 patients) enough?</p><p>3. What is the accuracy of the model?</p><p>4. I think there is no scope of this work shown in this &quot;Introduction part&quot;.</p><p>5. Please identify the innovation point in the paper.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. Several claims would need to be revised or toned down throughout the manuscript that describe the mathematical model as mechanistic and translatable. For example,</p><p>a. 'senescence markers (10) such as CD27, Tim‐3, CD57, and/or T‐cell receptor (TCR) repertoires (11)'. Only CD57 is a senescence marker among the listed proteins.</p><p>b. 'Our method may be implemented directly into clinical practice, as it relies on standard‐of‐care imaging and pathology' in Line 79,</p><p>c. 'the merit of this approach will rely on its future ability to reliably predict early individual patient response with the goal of improving personalized cancer care.'</p><p>d. Line 204-205: 'the model may be adaptable to other types of checkpoint inhibitors affecting the CTLA‐4 pathway'. Studies have described the effect of aCTLA4 therapies to be mediated in peripheral lymphoid organs rather than the tumour microenvironment. Therefore, the model that considers chemotaxis and intratumoural Ab activity will likely not apply to aCTLA4 therapies.</p><p>2. In addition to the assumptions described in the text, are the following assumptions implied:</p><p>a. The parameters µ and λ are considered constant over time, which implies that the ratio of cancer cells and immune infiltration remains the same over the treatment course.</p><p>b. Every cancer cell is assumed to have the same proliferation rate.</p><p>c. Each tumour cell has the same likelihood to be recognized by the immune system.</p><p>3. The cutoff used to split the µ and λ parameters and compare to responders and non-responders was done 'by maximizing the Youden's J statistic revealed cutoff thresholds where sensitivity'; A correction method needs to be applied to account for multiple testing correction. How does the result compare to using the median values and quantiles? How do changes in cutoff affect the Roc curve?</p><p>4. The manuscript text refers to Table S1 and supplementary figures, but supplementary information wasn't submitted for review. Unfortunately, the work on model sensitivity was not provided.</p><p>5. The work builds on a recent publication by the authors.</p><p>a. The manuscript could benefit from more information on the model, even if described previously elsewhere. For example, parameters in the methods and in Figure 1 are introduced but not described.</p><p>b. Importantly, the novelty of this study compared to the previous publication should be highlighted. The comparison with clinical and histology data appears to be the main novelty, which is why demonstrating the correlation with clinical data per patient, would be crucial. It is not clear why the calibration and validation dataset are different from the previous study. How do the estimated parameters differ?</p><p>6. The sensitivity and specificity of the λ parameter are low. Does it have an additive predictive value to the µ parameter?</p><p>7. How does the predictive value of the parameters compare to previously reported biomarkers of response such as TMB, % PDL1+ cells, T cell count? A predictive model controlling for age, stage, etc. should be implemented to account for these confounders.</p><p>8. How does the predictive value of the parameters change when the validation cohort is swapped with one of the calibration cohorts? How robust are the parameters to cross-validation? How does the predictive classification change with a different cancer type?</p><p>9. There is a lack of robust predictors of immunotherapy response due to a large number of confounder, such as heterogeneity at molecular and cellular level, immune escape, immunosenescence, etc. How does the model overcome this?</p><p>10. Figure 4 could be more clear and informative.</p><p>11. The published cohort in JITC has 72 patients but only 64 patients were included in the validation cohort, why is that so?</p><p>12. Which other pathological parameters correlate with λ and µwhen measured per patient, not per response group?</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>1) In the Figure 2, it would be helpful to show different cancer types as different panel.</p><p>2) An additional figure is favorable to show whether those key parameters were cancer type-specific or the antibody drugs.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.70130.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Multiple parameters could reflect treatment efficacy of immunotherapy to cancers while three specific parameters were included in this model, the selection process and reasons for choosing these three parameters need to be described in detail, the definition of the three parameters seems to in discordant with clinical setting which requires further explanation.</p></disp-quote><p>This point is well-taken. Mathematically, these are model-derived terms (i.e., after simplifying the initial model, composed of a system of differential equations) that allow for a closed-form solution, reducing the equation in a way that makes it possible to obtain unique solutions when only a few data points are available (a relatively common problem when using clinically-derived data), while also providing easy to interpret results and direct comparison to measurable parameters; we have now clarified this point on lines 222-225 of the revised manuscript. In fact, in the often chaotic, real world of day-to-day clinical practice, such simple indicators (or measures) are more likely to see adaptation, and it might likely (at least in part) explain the widespread success of the RECIST criteria. We also believe such simple measures (the values of which can be readily determined from stand-of-care measurements in current clinical practice) presents a major potential advantage for “translating” mathematical modeling-based predictions into clinical applications.</p><p>In order to help clarify the rationale behind this design process, we have now added the following text, lines 188-191:</p><p>“By reducing the model to this closed-form solution, we present the model in a form that combines related biological processes (see Figure 1) into only a few easy-to-interpret values, while also ensuring the ability to obtain unique solutions when only minimal data are available.”</p><disp-quote content-type="editor-comment"><p>2) As a heterogenous entity, different types of cancer possess distinct features, rationality to employ this model as one fit-in-all with a relatively small training cohort requires additional discussion after validated in a large-scale validation cohort.</p></disp-quote><p>Agreed: We have now added more discussions on this point, lines 474-476, 548-550, and 568-574. We have also softened the tone in line 470, by changing “demonstrates” to “suggests” that the overlaying master equation may be universally applied.</p><p>Lastly, because our calibration cohort consisted of n=189 patients and our validation cohort contained only n=64 patients, we believe that there may have been some inadvertent confusion regarding the number of patients in each cohort. This was likely due to undisciplined verbiage in the original text. We have now reworked this sentence (lines 55-58) to now read as follows:</p><p>“The model was calibrated by fitting it to a compiled clinical tumor response dataset (<italic>n</italic> = 189 patients) obtained from published anti-PD-1 and anti-PD-L1 clinical trials, and then validated on an additional validation cohort (<italic>n</italic> = 64 patients) obtained from our in-house clinical trials.”</p><disp-quote content-type="editor-comment"><p>3) As a novel model evaluation of the sensitivity and accuracy needs to be addressed, and comparison of this model with current applied parameters for predicting immunotherapy treatment efficacy requires to be supplemented.</p></disp-quote><p>Thank you for bringing out this essential suggestion for discussion.</p><p>First, to assess the accuracy of the model in the revision work, we have calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV); these are now provided in lines 390-400.</p><p>Moreover, we recognize that the novelty of the work presented in this work, which uses immunohistochemical (IHC) measurements to inform the model, might apparently have lost some of its central focus as originally presented. In fact, the model has already been demonstrated to perform reliably to predict patient response and even survival (e.g., PMID: 32426472), but this published work was done with a different approach (i.e., by using CT scan-based imaging data). While we have reported similar results here, the purpose of this current work is to evaluate how our new method of informing model parameters from IHC measurements compares to the previous (already established), imaging-based method. The purpose for doing so is two-fold: (i) Clinical data may often be convoluted/complex and measurements may be missing; thus, having multiple ways to inform the model (i.e., to determine model parameters) increases its ability to robustly handle a wider range of clinical scenarios; and (ii) IHC measurements may be collected at far earlier time points (relative to start of treatment) than imaging-based follow-up assessment of tumor responses; thus, this strategy potentially enables prediction tumor responses at an earlier time point than it was previously possible. We have revised the manuscript in several places to help bring this focus into greater clarity, as well as added discussion, lines 157-160, and 439-442.</p><p>Finally, we are actually unaware of any currently applied, clinically used parameters for predicting immunotherapy response, although several possible methods have been published in the last few years including transcriptomic rubrics (PMID 30127394), machine learning algorithms (PMID 33208341), genomic approaches (PMID 33307238) such as tumor mutational burden (PMID 31315901), among others (PMID 34112949<bold>).</bold> Instead, most “currently applied parameters” merely document tumor responses that have already occurred as opposed to predicting it a priori; these include the standard RECIST v1.1 and even the newer proposed response assessment rubrics specific for immunotherapy (iRECIST). As such, our model parameters, which can be determined in multiple ways (e.g., from early time point imaging and/or histopathology data), presents a clear advantage over the standard measures currently used in the clinic for predicting treatment outcome and patient survival. This key advantage of the methodology introduced here is now mentioned in the lines 126-127, 129-131, and 160-163 of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>The authors demonstrate a translational mathematical model dependent on three key parameters for describing efficacy of checkpoint inhibitors in human cancer. This paper describes some very interesting work. However, it remains questions that need to be addressed as follows:</p><p>1. The authors need present why they select these three parameters for describing efficacy of checkpoint inhibitors in human cancer. How about other factors?</p></disp-quote><p>This point is again well-taken. The details of the full model derivation have recently been reported elsewhere (e.g., PMIDs 32426472, 33398132); however, we have now added it to the SI of this manuscript as well (Appendix 1, lines 14-103); and we have now added a reference to the derivation in the revised main text (line 192). We have also added a clarification as to why this approach was implemented in the revised main text (lines 188-191).</p><p>Additional details relative to this appropriate concern are also provided in this letter (please see Essential Revisions, point #1). We further note that, beyond those points, we have endeavored to carefully reduce the full model (wherein all relevant, key biological parameters must be included at mathematical derivation for scientific integrity) such that the model may be informed through clinically-measurable quantities. For example, how can we measure cytokine diffusion in vivo or in patients during the course of actual treatment? We cannot, at least by using the currently available technologies in a standard outpatient clinic or inpatient hospital setting. We have now found a way to solve this dilemma by further simplifying the model to reduce the parameter space of the model through biologically sound, reasonable assumptions (please see the newly added section on mathematical model derivation; Appendix 1, lines 14-103 of the revised work). That is, by focusing on only parameters that can actually be measured in current clinical practice, it allows us to focus this work on demonstrating additional ways that the model may be used for clinical predictions under current clinical practice, with a focus here on IHC measurement. We take our successful results by using only these limited data (% change in tumor volumes vs. time or IHC staining) as evidence of the robustness of the model performance.</p><disp-quote content-type="editor-comment"><p>2. How can the authors make sure that this model is suitable for all human cancer? Is the clinical tumor response dataset (n = 189 patients) enough?</p></disp-quote><p>The Referee has appropriately expressed some caution over the sample size of the patient cohorts. While future studies will obviously be required in order to fully address “all human cancer” as he/she inquired, we have now softened the tone of model results, clarifying that the model has only been tested in the cancer types described in the revised manuscript (lines 474-476, 548-550, and 568-574). Specifically, there were n=55 responders and n=134 non-responders. Assuming type-1 error α=0.05 and type=2 error β=0.1, the measured difference between means for μ responders vs non-responders (0.054 vs. 0.013, respectively) with population variance S<sup>2</sup><sub>μ</sub> = 0.00394 (data not shown in the manuscript) could be detected by a minimum necessary sample size of n=52 patients (comparison of 2 independent means). Equivalent analysis for <italic>Λ</italic> revealed a minimum sample size of n=51, so the calibration dataset is sufficiently large enough for the cancer types that have been reported here.</p><disp-quote content-type="editor-comment"><p>3. What is the accuracy of the model?</p></disp-quote><p>To assess the accuracy of the model, we have now calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV); these are now provided in lines 390-400.</p><disp-quote content-type="editor-comment"><p>4. I think there is no scope of this work shown in this &quot;Introduction part&quot;.</p></disp-quote><p>We have clarified this in the revised manuscript, lines 157-160.</p><disp-quote content-type="editor-comment"><p>5. Please identify the innovation point in the paper.</p></disp-quote><p>We have clarified this in the revised manuscript, lines 157-160.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. Several claims would need to be revised or toned down throughout the manuscript that describe the mathematical model as mechanistic and translatable. For example,</p><p>a. 'senescence markers (10) such as CD27, Tim‐3, CD57, and/or T‐cell receptor (TCR) repertoires (11)'. Only CD57 is a senescence marker among the listed proteins.</p></disp-quote><p>Agreed. Tim-3 is actually a marker of T-cell exhaustion, and loss of CD27 is associated with immune incompetence, exhaustion, or premature senescence (e.g., PMID: 15882352). We have now corrected this sentence to read (lines 121-124 of the revised manuscript):</p><p>“An accumulating body of evidence has established that certain immunological features, including T-cell exhaustion (e.g., Tim-3) and exclusion (9), senescence markers (10) such as CD57, or immune incompetence, exhaustion, or premature senescence (e.g., loss of CD27) (11, 12) could perhaps reflect or even predict sensitivity and resistance to checkpoint inhibitor-based cancer immunotherapy.”</p><disp-quote content-type="editor-comment"><p>b. 'Our method may be implemented directly into clinical practice, as it relies on standard‐of‐care imaging and pathology' in Line 79,</p></disp-quote><p>We take this to mean that, although our method could be translated to the clinic by using only already-established techniques, it must be rigorously validated in future studies, just as with any predictive clinical parameter or tool. We have added this caveat to the discussion of the revised manuscript, lines 474-476, 548-550, and 568-574.</p><disp-quote content-type="editor-comment"><p>c. 'the merit of this approach will rely on its future ability to reliably predict early individual patient response with the goal of improving personalized cancer care.'</p></disp-quote><p>This goes along with the previous point (b); please see our response above.</p><disp-quote content-type="editor-comment"><p>d. Line 204-205: 'the model may be adaptable to other types of checkpoint inhibitors affecting the CTLA‐4 pathway'. Studies have described the effect of aCTLA4 therapies to be mediated in peripheral lymphoid organs rather than the tumour microenvironment. Therefore, the model that considers chemotaxis and intratumoural Ab activity will likely not apply to aCTLA4 therapies.</p></disp-quote><p>We have recently demonstrated this to be the case (PMID 32426472). That being said, to avoid any further confusion, we have removed this statement (as well as mention of cell-based immunotherapies at this location) from the main text.</p><p>We however emphasize that this is not the intended implication of the model assumption as described in Appendix 1, lines 25-26 (that is, in our model we assume that the therapeutic cite of action occurs within the tumor microenvironment). The PD-1 and CTLA-4 receptors that are targeted in many types of immunotherapy are expressed on T cells; which may not be located in the tumor at time of systemic drug administration (while the PD-L1 receptor, located on the cancer cell plasma membrane, will always be in the tumor). This implies that, in the case of anti-CTLA-4 and anti-PD-1 therapy, a portion of the drug can potentially bind to T-cells outside the tumor (e.g., in the thymus, peripheral blood, etc.). However, our model assumes that (i) drug diffuses through the tumor to its binding site (as per Eqs. S3, S4), (ii) all drug binding occurs within the tumor, and (iii) all drug effects (e.g., tumor kill) occurs within the tumor microenvironment. That is, all “sites of therapeutic action” are located within the tumor.</p><p>We recognize that this statement may indeed be inadvertently confusing, so we have now clarified this in the model description of the revised Appendix 1 as follows (Appendix 1, lines 26-28):</p><p>“that is, because our model only describes the tumor region and the factors and processes contained therein, we have made the assumption that all key mechanisms such as drug binding occur only within the tumor.”</p><disp-quote content-type="editor-comment"><p>2. In addition to the assumptions described in the text, are the following assumptions implied:</p><p>a. The parameters µ and λ are considered constant over time, which implies that the ratio of cancer cells and immune infiltration remains the same over the treatment course.</p></disp-quote><p>It is established that, for example, T-cells do experience “burnout” and loss of cytotoxic efficacy over their lifetimes (e.g., our reply to point 1a, above), and will influx/efflux the tumor over time, and as such it should not be expected that T-cell density remains constant in the tumor at all times. Thus, these parameters represent the average value of these fluctuating parameters. We take this to be a reasonable assumption because (i) these quantities are not directly measurable, and (ii) even in our in-house data, times between patient reassessment ranged ~4-6 weeks, so even if you could measure these, you would be forced to average between these times either way, and (iii) these processes take place at far shorter times than patient reassessments. By presenting the model in this reduced-form, we enable simplified interpretation of the results while also providing a single, easy to understand scalar that contains significant information about the treatment response. We also note here that RECIST and its immune checkpoint inhibitor counterparts provide readout in a similar manner. These points are now emphasized in the revised manuscript (lines 535-542).</p><disp-quote content-type="editor-comment"><p>b. Every cancer cell is assumed to have the same proliferation rate.</p></disp-quote><p>This is indeed a correct observation. Because we do not explicitly model individual cancer cells, we must use the average proliferation rate across the entire tumor in order to capture the total proliferation and proliferation rate of the cancer cell population. Also, understandably, this is not something that would even be measurable on a per-cell level in the clinic or in vivo. This approach is commonly used in mathematical modeling studies based on continuum representations. We have now pointed out this limitation in the revised manuscript (lines 537-538, with accompanying discussion in lines 535-542).</p><disp-quote content-type="editor-comment"><p>c. Each tumour cell has the same likelihood to be recognized by the immune system.</p></disp-quote><p>Again, this is correct, for the same reasons provided in the previous reply. Future single-cell imaging may shed light in these limitations and refine the methodology introduced here.</p><disp-quote content-type="editor-comment"><p>3. The cutoff used to split the µ and λ parameters and compare to responders and non-responders was done 'by maximizing the Youden's J statistic revealed cutoff thresholds where sensitivity'; A correction method needs to be applied to account for multiple testing correction. How does the result compare to using the median values and quantiles? How do changes in cutoff affect the Roc curve?</p></disp-quote><p>We appreciate the attention to detail. We believe the suggestion for multiple testing correction here is likely based on a potential misunderstanding. We did not identify an “ideal” threshold for each cohort by Youden’s J statistic, we only identified one single threshold for <italic>μ</italic> and <italic>Λ</italic> (that is, one for each parameter) in the calibration cohort, and then assessed the performance of the same threshold values in the validation cohorts. The results show that the thresholds were able to satisfactorily separate responders from non-responders, which in our opinion has proven the validity of <italic>μ</italic> and <italic>Λ</italic> for this purpose already, i.e., to test how these carefully designed thresholds would perform across independent datasets. Therefore, it is a little unclear as to what value testing other cutoff thresholds would add to the manuscript. However, in order to avoid any confusion, we have clarified this in the text, lines 392-393:</p><p>“Testing these same response threshold values (identified in the calibration cohort) in the validation cohort”.</p><disp-quote content-type="editor-comment"><p>4. The manuscript text refers to Table S1 and supplementary figures, but supplementary information wasn't submitted for review. Unfortunately, the work on model sensitivity was not provided.</p></disp-quote><p>We have now verified that we had originally uploaded both main text and SI at time of initial submission. We do not know why the SI (now Appendix 1) has not been properly provided to the Referees for external peer-review, but regret that this may have indeed been the case. We will be sure to submit both revised main text and SI when we resubmit the revised draft; we will also check with the editorial office to make sure that they have been fully transmitted to the Referees.</p><disp-quote content-type="editor-comment"><p>5. The work builds on a recent publication by the authors.</p><p>a. The manuscript could benefit from more information on the model, even if described previously elsewhere. For example, parameters in the methods and in Figure 1 are introduced but not described.</p></disp-quote><p>Agreed. We have added a detailed model derivation, including discussion of individual parameters and assumptions made, in Appendix 1 (Appendix 1, lines 14-103); the reader is also now referred to this on line 192.</p><disp-quote content-type="editor-comment"><p>b. Importantly, the novelty of this study compared to the previous publication should be highlighted. The comparison with clinical and histology data appears to be the main novelty, which is why demonstrating the correlation with clinical data per patient, would be crucial. It is not clear why the calibration and validation dataset are different from the previous study. How do the estimated parameters differ?</p></disp-quote><p>Thank you for this suggestion. Unfortunately, we have been unable to obtain any per-patient data that contains both patient response to ICI therapy and also IHC measures of PD-L1 expression or CD8<sup>+</sup> tumor-infiltrating lymphocyte counts from the same patients that would enable this direct comparison. While we are working towards in-house collection of this data, we believe that this study represents an important step towards this goal. The calibration cohort in this work was expanded from the literature cohort used in previous work (PMID: 32426472), because we found more published data since that time, and wanted to use all data available. Model parameters are the same (per-patient) between studies when estimated by tumor volume measurements (although means have changed due to addition of new data); these serve as the established baseline for comparison with the IHC-based estimation of model parameters presented in this work.</p><p>We however fully agree that further emphasis should be placed on the novelty of informing model parameters by IHC; therefore, we have further emphasized this point in the manuscript, lines 157-160 and 439-442.</p><disp-quote content-type="editor-comment"><p>6. The sensitivity and specificity of the λ parameter are low. Does it have an additive predictive value to the µ parameter?</p></disp-quote><p>It is correct that µ was found to have higher sensitivity and specificity in the results shown. We have now included a full description of the results for <italic>Λ</italic> as well, (i) for sake of scientific completeness, because it is an integral part of the model reduced-form and we intended to show the complete set of our results, and (ii) because we have shown previously (PMID: 33398132) that <italic>Λ</italic>×<italic>μ</italic> may also be used as a dug-disease specific measure of treatment response.</p><disp-quote content-type="editor-comment"><p>7. How does the predictive value of the parameters compare to previously reported biomarkers of response such as TMB, % PDL1+ cells, T cell count? A predictive model controlling for age, stage, etc. should be implemented to account for these confounders.</p></disp-quote><p>We were unable to obtain TBM, % PDL1+ cells, or intratumoral T cell count for the patients studied. This was not in the literature-derived cohort, and needle biopsies were not required in the in-house studies, so we have been as yet unable to do these analyses at this time. Age, stage, etc. are well suited for certain kinds of statistical models (e.g., Cox proportional hazards), and we agree that this could be something interesting to investigate, e.g., maybe we could find out whether the model could serve better for age groups of patients. That said, since this is not the focus of this work, we have decided to put it as part of our future work, lines 568-574:</p><p>&quot; Towards this end, we are currently pursuing in-house collection of per-patient, paired IHC measures of PDL1 or T-cell counts with tumor response, which will enable us to directly correlate IHC measures of interest with tumor response, while also allowing for examination of additional patient parameters, such as tumor stage or patient age.”</p><disp-quote content-type="editor-comment"><p>8. How does the predictive value of the parameters change when the validation cohort is swapped with one of the calibration cohorts? How robust are the parameters to cross-validation? How does the predictive classification change with a different cancer type?</p></disp-quote><p>This point is well-taken. In fact, we have shown similar results to the analysis requested here previously, in PMID: 32426472, Figure 5. In order to shed further light on parameter robustness across cancer types, as suggested, we have added a new analysis wherein we performed a ‘leave-one-cancer-type-out’ validation analysis with the calibration cohort (made up of 6 different cancer types). That is, the model parameter rages for each response category from the remaining 5 cancer types are compared to the range from the left-out type; this was repeated for all 6 cancer types, and the results are shown in the new figure, Appendix 1-figure 3. We have also added discussion on this new analysis in the main text, lines 356-361. We have also now referred the reader to this publication (PMID: 32426472) in case they are interested, line 360. We would like to thank the Referee for his/her helpful suggestion.</p><disp-quote content-type="editor-comment"><p>9. There is a lack of robust predictors of immunotherapy response due to a large number of confounder, such as heterogeneity at molecular and cellular level, immune escape, immunosenescence, etc. How does the model overcome this?</p></disp-quote><p>This is a fair point, and the Referee is correct that these cofounding factors are known to be relevant in ICI treatment and outcome. In the model as presented, we approximate heterogeneous parameters (such as immune cell distribution or infiltration rates, immune checkpoint ligand densities, ICI drug perfusion, immune cell activation and killing capacity, etc.) based on their spatiotemporal averages. As such, we overcome these by indirectly capturing their contributions to the overall system, allowing us to characterize the system in order to make predictions without explicit measures of these factors.</p><p>Indeed, complete characterization of these factors remains clinically prohibitive, if even possible, and we believe that the high cost (time, money, and inconvenience of clinical adoption) of such models that must capture them to function will not progress beyond the research or hypothesis-generating stage. We also believe that these low-level factors contribute to overarching mechanisms that are more readily measurable, allowing their effects (including those not as yet discovered) to be captured indirectly. By developing methods to inform more parameters in our model by using clinically-available measures, we are moving forward to a place where one day we may be able to mathematically back-calculate these unmeasurable factors, which we hope will be of benefit to both researchers and clinicians.</p><disp-quote content-type="editor-comment"><p>10. Figure 4 could be more clear and informative.</p></disp-quote><p>If the Referee could perhaps help us by further clarifying his/her comment, that would be greatly appreciated; we are open for constructive suggestions.</p><disp-quote content-type="editor-comment"><p>11. The published cohort in JITC has 72 patients but only 64 patients were included in the validation cohort, why is that so?</p></disp-quote><p>Some patients were excluded due to inclusion criteria specific to this study, which were different than those in JITC. Details are now provided on lines 263-266 of the revised manuscript:</p><p>“a total of 95 patients were obtained; however, 18 left the study after admission, 11 were removed due to lack of pre-treatment measurements, one was excluded because all indexed lesions were treated with XRT, and one discontinued treatment but continued follow-up”.</p><disp-quote content-type="editor-comment"><p>12. Which other pathological parameters correlate with λ and µwhen measured per patient, not per response group?</p></disp-quote><p>Thank you for the comment. Unfortunately, only % change in tumor burden over time was available for our calibration cohort; thus, we were unable to investigate pathological parameters in this study. Please also see our reply to Referee #2 Public Review comment 2, above.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>1) In the Figure 2, it would be helpful to show different cancer types as different panel.</p></disp-quote><p>We appreciate this comment; however, we elected this format to simply highlight the differences in parameter values while keeping our focus on the main innovation of this revised manuscript: i.e., by using IHC to inform model parameters. We have shown results similar to those requested here in a previous study however; we have now added text to point the interested reader to these results, line 771.</p><disp-quote content-type="editor-comment"><p>2) An additional figure is favorable to show whether those key parameters were cancer type-specific or the antibody drugs.</p></disp-quote><p>Please see the previous comment. We have shown cancer-drug specific results in our previous work; we have added a reference to point the interested reader to this analysis, line 771.</p></body></sub-article></article>